

# **24-hour-restraint stress induces long-term depressive-like phenotypes in mice**


Xixia Chu, Ying Zhou, Zhiqiang Hu, Jingyu Lou, Wei Song, Jing Li, Xiao Liang, Chen Chen, Shuai Wang, Beimeng Yang, Lei Chen, Xu Zhang, Jinjing Song, Yujie Dong, Shiqing Chen, Lin He, Guoqing Xie, Xiaoping Chen, Weidong Li

Supplementary information


## Supplementary Figures




**Figure S1. The apparatus of the 24-hour-restraint.** The restraint apparatus is a ventilated clear plastic tube (3cm in diameter×10cm). The holes (0.5 cm in diameter) in the head and along the sidewall of the tube enabled air flowing and keep warm as well. Animals could move head and anterior limb, but the body and hindquarters were not able to move or turn around.




**Figure S2. The changes of serum corticosterone (CORT) level.** The serum CORT levels were tested 24 hours before the restraint (-24h), within the restraint (1h, 12h and 23h) and after the restraint (48h). The restraint and control groups were displayed in red and black respectively. Two-way ANOVA with repeated-measure (N=7 for each group) suggested CORT levels between two groups were different ( $p < 0.001$ ). Significant interactions were detected by additional unpaired t-tests followed by correction with Holm-Bonferroni method. Data are presented as mean  $\pm$ SEM, \* $P < 0.05$ , \*\*  $P < 0.01$ .




**Figure S3. Changes of body weight.** The weight of mice was measured 24 hours before restraint (Day-1), immediately after restraint was ended (restraint), 1 day after restraint (Day 1), and 5 weeks after the restraint (Week 5). Three-way ANOVA with repeated-measure suggested body weights of mice with or without restraint were different ( $p < 0.05$ ). Significant interactions of time points and stress/restraint were detected by two-way ANOVAs followed by correction with Holm-Bonferroni method. Data are presented as mean  $\pm$  SEM, \* $P < 0.05$ , \*\*\*  $P < 0.001$ .




**Figure S4. Sucrose preference adaptation and pre-SPT before the 24-hour-restraint of S group showed no difference between control and restraint mice. A.** Sucrose preference (%) in the 3-day adaption (two-way ANOVA,  $p=0.788$ ). **B.** Total consumption (water + sucrose) in 3-day adaptation (two-way ANOVA,  $p=0.278$ ). **C.** Sucrose consumption percentage in the 24-hour sucrose preference test before restraint (t-test,  $p=0.103$ ). **D.** Total consumption in the 24-hour sucrose preference test before restraint (t-test,  $p=0.163$ ).  $N=24$  vs.  $25$ , respectively. Data are presented as mean  $\pm$ SEM.



**Figure S5. Sucrose preference adaptation and pre-SPT before 24-hour-restraint of L group showed no difference between control and restraint mice. A.** Sucrose consumption in the 3-day adaption (two-way ANOVA,  $p=0.61$ ). **B.** Total consumption (water + sucrose) in the 3-day adaptation (two-way ANOVA,  $p=0.84$ ). **C.** Sucrose consumption percentage in the 24-hour sucrose preference test before restraint (t-test,  $p=0.24$ ). **D.** Total consumption in the 24-hour sucrose preference test before restraint (t-test,  $p=0.14$ ).  $N=25$  vs.  $27$ , respectively. Data are presented as mean  $\pm$ SEM.



**Figure S6. Behavioral experiments without significant differences of the short-term group.** **A.** The total distances in the open field experiment ( $p=0.937$ ,  $N=15$  vs.  $15$ ). **B.** The dwell time between in the open arms and in the close arms in the elevated plus maze experiment ( $p=0.860$  for open arm comparison,  $p=0.957$  for close arm comparison,  $N=15$  vs.  $15$ ). **C.** Time in mouse cage and empty cage in the sociability test ( $p=0.272$  and  $0.325$ ,  $N=15$  vs.  $15$ ). **D.** The sniffing time between in mouse cage cell and empty cage cell in the sociability test ( $p=0.101$  and  $0.890$ ,  $N=15$  vs.  $15$ ). **E.** The %PPI in the prepulse inhibition test ( $p=0.952$ ,  $0.707$  and  $0.175$  for  $76$ db,  $79$ db and  $85$ db respectively,  $N=15$  vs.  $15$ ). Data are presented as mean  $\pm$ SEM.



**Figure S7. Behavioral experiments without significant differences of the long-term group.** **A.** The total distances in the open field experiment ( $p=0.866$ ,  $N=15$  vs. 15). **B.** The dwell time between in the open arms and in the close arms in the elevated plus maze experiment ( $p=0.112$  for open arm comparison,  $p=0.170$  for close arm comparison,  $N=15$  vs. 15). **C.** The dwell time between in mouse cage cell and empty cage cell in the sociability test ( $p=0.913$  and  $0.563$ ,  $N=13$  vs. 15). **D.** The sniffing time between in mouse cage cell and empty cage cell in the sociability test ( $p=0.895$  and  $0.769$ ,  $N=13$  vs. 15). **E.** The %PPI in the prepulse inhibition test ( $p=0.865$ ,  $0.815$  and  $0.302$  for 76db, 79db and 85db respectively,  $N=15$  vs. 15). Data are presented as mean  $\pm$ SEM.



## **Supplementary methods**

### **Corticosterone assay**

To measure the level of CORT, 100µl blood samples were collected from tail vein at 5 time points (24 hours before restraint, 1, 12, 23 and 48 hours after the onset of restraint). Blood samples were centrifuged at 1,000g for 10minutes, and serum was collected. The level of CORT was measured by radioimmunoassay using the corticosterone kit (MP Biomedicals, USA).

### **Open Field test (OFT)**

All animals were allowed to adapt to the experimental room for at least 1 hour before the test. Open field test (OFT) is commonly used for measuring the exploratory behavior and general activity of animals. Mice were allowed to freely explore the chamber for 20 min in a square plexiglass box (27.5×27.5×18 cm). The total distance of movement was recorded by software of Med Associates inc.

### **Elevated Plus-maze test (EMP)**

The apparatus consisted of consisted of two open arms (30×8 cm) and two closed arms (30×8 cm, surrounded by 15 cm-high walls), positioned opposite each other. Mice were placed in the center with its nose directed toward the closed arm. Each session lasted 5 min and maze was cleaned with alcohol after each test. Behavior of each mouse was continuously videotaped by a video camera placed above the

apparatus.

## **Social Interaction test (SIT)**

The apparatus is a plexiglass box (60×40×50 cm) consisted of three chambers divided by plexiglass walls with holes in the middle to allow animals to move between chambers. Inverted steel cages (8 in diameter × 10 cm) were placed in each side of the end chambers. The test consists of two sessions. In the first session, mouse was placed in the central chamber and allowed to habituate to the apparatus for a 10 min. In the second session, a stimulus juvenile male mouse (4-5 weeks) was placed in the inverted cage used for the social compartment and the test mouse was placed in the middle chamber to explore for 5 min. Behavioral tests were recorded by a video camera, and the EthoVision XT video tracking system (Noldus).

## **Prepulse Inhibition test (PPI)**

The test had a total of 90 trials by The SR-LAB™ Startle Response System. To evaluate the startle response, each of the first 10 trials is consisted of a 40 ms 120 dB “pulse alone” startle stimuli. The rest of the 80 trials are consisted of random delivery of: 20 “pulse alone” startle stimuli, 30 “pre” stimuli (at 76, 79 and 85dB), and 30 “pre-pulse” trials that consisted of a single 120 dB pulse preceded by a 20 ms pre pulse. PPI was defined as the percent reduction in startle magnitude in each prepulse condition compared to the magnitude of response in the pulse-alone condition.

## PET scanning

After a PET scan with the trans-PET<sup>®</sup> BioCaliburn<sup>®</sup> LH system, PET images were reconstructed by use of 3D OSEM method, with the voxel size of  $0.5 \times 0.5 \times 0.5 \text{ mm}^3$ . This trans-PET<sup>®</sup> system has the radial, tangential and axial resolutions of 0.95 mm FWHM, 1.05 mm FWHM and 1.01 mm FWHM, respectively, at the center of the AFOV. The absolute sensitivity measured at the center of the scanner is 2.04% with an energy window of 350-650 keV and coincidence timing window of 5 ns. The noise equivalent count-rate reaches a peak value of 62 kcps at 28 MBq for the mouse-sized phantom. The scatter fraction is 8.4% for the mouse-sized phantom. For the Derenzo phantom study, the 1.0 mm diameter rods can be clearly resolved<sup>1</sup>.

In this work, the volume of the VOIs ranges from  $5 \text{ mm}^3$  to  $150 \text{ mm}^3$ . Among the brain areas, the inferior colliculus has the smallest VOI of  $5.1 \text{ mm}^3$ . Hence, it is possible to differentiate between different brain areas according to the Derenzo phantom study with this PET system. In addition, to obtain the quantitative data of each VOI, an imaging processing method is employed. An <sup>18</sup>FDG uptake was calculated in each VOI of each subject by use of an individual normalized parametric images and an in-house generated VOI-template<sup>2</sup>. The VOI template for whole-brain quantification of the <sup>18</sup>FDG-PET signal was created by use of the brain atlas generated from the MRI or immunohistochemical images<sup>3</sup>. The PET scan for each subject in the study was aligned to the <sup>18</sup>FDG-mouse-template with the VOI template. The percent injected dose per cubic centimeter of tissue (%ID/cc tissue) was obtained

for each VOI by dividing the mean  $^{18}\text{F}$ FDG activities of the injected dose.

As the brain areas are small, the quantitative imaging should be improved by developing image analysis methods based on understanding the physical factors affecting the precision, such as spatial resolution, noise, and some unclear ones. The partial volume effects may result that the small objects appear to be smeared out and have lower activity concentration in the reconstructed PET image, while spill-over effects lead to higher activity concentration. How these factors affecting the PET imaging analysis and the smallest areas that can be quantitated by a PET scanner need to be further studied.

#### References:

1. Wang, L. et al. Performance evaluation of the Trans-PET® BioCaliburn® LH system: a large FOV small-animal PET system. *Phys Med Biol* 60, 137–50 (2015).
2. Mirrione, M. M. et al. Increased metabolic activity in the septum and habenula during stress is linked to subsequent expression of learned helplessness behavior. *Front Hum Neurosci* 8, 29 (2014).
3. Ma, Y. et al. In Vivo 3D Digital Atlas Database of the Adult C57BL/6J Mouse Brain by Magnetic Resonance Microscopy. *Front Neuroanat* 2, 1 (2008).

**Table S1 Enriched KEGG pathways.**

| Tissue                                  | Time                      | Enriched pathways                             | p-value  | Involved genes  |
|---|---------------------------|---|--|---|
| prefrontal Cortex                       | 35d                       | Antigen processing and presentation           | 8.37E-05   | CD8B1//H2-Q10//HSPA1A//HSPA1B                               |
|   |                           | Protein processing in endoplasmic reticulum   | 0.014  | HSPA1A//HSPA1B//PDIA4                                       |
|   |                           | Adipocytokine signaling pathway               | 0.018  | IRS2//PRKAG2  |
|   |                           | Endocytosis                                   | 0.028  | H2-Q10//HSPA1A//HSPA1B                                      |
|   |                           | MAPK signaling pathway                        | 0.041  | CACNA2D1//HSPA1A//HSPA1B                                    |
|   |                           | Neuroactive ligand-receptor interaction       | 2.86E-06   | ADORA2A//DRD1A//DRD2//HTR1D//NMBR//NTS                      |
|   |                           | Dopaminergic synapse                          | 0.001  | DRD1A//DRD2//KCNJ5  |
|   |                           | Gap junction                                  | 0.007  | DRD1A//DRD2   |
|   |                           | Serotonergic synapse                          | 0.016  | HTR1D//KCNJ5  |
|   | Calcium signaling pathway | 0.03  | ADORA2A//DRD1A                                       |   |
|   | 2d                        | T cell receptor signaling pathway             | 0.009  | CD8B1//IL5//MAPK12//NFATC1//PTPRC                           |
|   |                           | Notch signaling pathway                       | 0.02   | DLL1//DLL4//KAT2A   |
|   |                           | Inositol phosphate metabolism                 | 0.035  | MIOX//PLCZ1//TPI1   |
|   |                           | Pancreatic secretion                          | 0.035  | ATP2B4//CELA2A//PLA2G12A//SCT                               |
| Neuroactive ligand-receptor interaction |                           | 0.037   | ADRA2B//ADRB3//CHRNA2//GABRB3//MC3R//NMUR2//NTS//SCT |   |
| Cardiac muscle contraction              | <0.001                    | ACTC1//COX8B//MYL3//TNNC1//TNNI3//TNNT2//TPM1 |  |   |
| Calcium signaling pathway               | 0.047                     | ADCY3//MYLK3//PLN//TNNC1//TRHR                |  |   |
| Hippocampus                             | 35d                       | MAPK signaling pathway                        | 0.001  | DUSP5//FGFR2//HSPA1A//HSPA1B//IKBKG//MYC//TRAF6             |
|   |                           | Endocytosis                                   | 0.008  | FGFR2//H2-M2//HSPA1A//HSPA1B//TRAF6                         |
|   |                           | B cell receptor signaling pathway             | 0.01   | IKBKG//INPP5D//PTPN6  |
|   |                           | Antigen processing and presentation           | 0.011  | H2-M2//HSPA1A//HSPA1B                                       |
|   |                           | Hedgehog signaling pathway                    | 0.032  | WNT3//WNT7B   |
|   |                           | Gap junction                                  | 0.001  | DRD1A//GUCY1B2//PRKG2//TUBA1C//TUBA3A                       |
|   |                           | Neuroactive ligand-receptor interaction       | 0.001  | ADORA2A//DRD1A//F2RL1//GABRR1//HTR1D//LEPR//SCT//TACR1//TRH |
|   |                           | Antigen processing and presentation           | 0.028  | H2-Q1//HSP90AB1//KLRC2                                      |
|   | Hippo signaling pathway   | 0.039   | BMP6//CRB2//CTGF//WNT6                               |   |
|   | 2d                        | Fatty acid metabolism                         | 0.027  | ACSL3//ALDH7A1  |
|   |                           | Hedgehog signaling pathway                    | 0.028  | BMP4//ZIC2  |
|   |                           | Arginine and proline metabolism               | 0.037  | ALDH7A1//P4HA1  |

Enrichments from up-regulated DEGs and down-regulated DEGs are shown in “red” and “green” respectively.

**Table S2 Enriched GO terms of DEGs.**

**A. Enriched GO terms of up-regulated DEGs in long-term PFC.**

| Term  | Count | PValue   | Genes                       | Fold Enrichment | Bonferroni  | Benjamini   | FDR         |
|---|-------|----------|-----------------------------|-----------------|-------------|-------------|-------------|
| GO:0007631~feeding behavior   | 4     | 2.70E-05 | CALCA, ADORA2A, DRD2, DRD1A | 62.68973472     | 0.014581416 | 0.014581416 | 0.039274176 |
| GO:0007188~G-protein signaling, coupled to cAMP nucleotide second messenger   | 4     | 3.39E-05 | CALCA, ADORA2A, DRD2, DRD1A | 58.13048128     | 0.018282456 | 0.009183395 | 0.049332702 |
| GO:0007187~G-protein signaling, coupled to cyclic nucleotide second messenger | 4     | 4.40E-05 | CALCA, ADORA2A, DRD2, DRD1A | 53.28627451     | 0.023696227 | 0.007961967 | 0.064112691 |
| GO:0045761~regulation of adenylate cyclase activity                           | 4     | 4.40E-05 | CALCA, ADORA2A, DRD2, DRD1A | 53.28627451     | 0.023696227 | 0.007961967 | 0.064112691 |
| GO:0019933~cAMP-mediated signaling  | 4     | 4.62E-05 | CALCA, ADORA2A, DRD2, DRD1A | 52.41272903     | 0.024888871 | 0.006281149 | 0.067379416 |
| GO:0031279~regulation of cyclase activity                                     | 4     | 4.86E-05 | CALCA, ADORA2A, DRD2, DRD1A | 51.56736243     | 0.026119231 | 0.005279295 | 0.070753527 |
| GO:0051339~regulation of lyase activity                                       | 4     | 4.86E-05 | CALCA, ADORA2A, DRD2, DRD1A | 51.56736243     | 0.026119231 | 0.005279295 | 0.070753527 |
| GO:0030817~regulation of cAMP biosynthetic process                            | 4     | 5.60E-05 | CALCA, ADORA2A, DRD2, DRD1A | 49.18733032     | 0.030041045 | 0.005070688 | 0.081536369 |
| GO:0019935~cyclic-nucleotide-mediated signaling                               | 4     | 5.86E-05 | CALCA, ADORA2A, DRD2, DRD1A | 48.44206774     | 0.031426656 | 0.004551193 | 0.085356188 |

|   |   |          |                                   |             |             |             |             |
|---|---|----------|-----------------------------------|-------------|-------------|-------------|-------------|
| GO:0030814~regulation of cAMP metabolic process                 | 4 | 6.13E-05 | CALCA, ADORA2A, DRD2, DRD1A       | 47.7190518  | 0.032852127 | 0.004166779 | 0.089291447 |
| GO:0030802~regulation of cyclic nucleotide biosynthetic process | 4 | 6.99E-05 | CALCA, ADORA2A, DRD2, DRD1A       | 45.67394958 | 0.037371644 | 0.004223043 | 0.101805776 |
| GO:0030808~regulation of nucleotide biosynthetic process        | 4 | 6.99E-05 | CALCA, ADORA2A, DRD2, DRD1A       | 45.67394958 | 0.037371644 | 0.004223043 | 0.101805776 |
| GO:0044057~regulation of system process                         | 5 | 7.36E-05 | CALCA, GSX2, ADORA2A, DRD2, DRD1A | 19.88293825 | 0.039305027 | 0.004001804 | 0.107176696 |
| GO:0030799~regulation of cyclic nucleotide metabolic process    | 4 | 7.92E-05 | CALCA, ADORA2A, DRD2, DRD1A       | 43.79693795 | 0.042263646 | 0.003918008 | 0.115416112 |
| GO:0051966~regulation of synaptic transmission, glutamatergic   | 3 | 8.52E-05 | ADORA2A, DRD2, DRD1A              | 199.8235294 | 0.045379667 | 0.003862652 | 0.124120704 |
| GO:0006140~regulation of nucleotide metabolic process           | 4 | 8.59E-05 | CALCA, ADORA2A, DRD2, DRD1A       | 42.62901961 | 0.045736564 | 0.003594716 | 0.12511946  |
| GO:0001975~response to amphetamine                              | 3 | 1.35E-04 | ADORA2A, DRD2, DRD1A              | 159.8588235 | 0.071081297 | 0.005252873 | 0.19699126  |
| GO:0031645~negative regulation of neurological system process   | 3 | 1.97E-04 | CALCA, DRD2, DRD1A                | 133.2156863 | 0.101674821 | 0.007122723 | 0.286334092 |
| GO:0014075~response to amine stimulus                           | 3 | 2.44E-04 | ADORA2A, DRD2, DRD1A              | 119.8941176 | 0.124511529 | 0.008276392 | 0.354976359 |
| GO:0010243~response to organic nitrogen                         | 3 | 2.44E-04 | ADORA2A, DRD2, DRD1A              | 119.8941176 | 0.124511529 | 0.008276392 | 0.354976359 |

|   |   |             |                                 |             |             |             |             |
|---|---|-------------|---------------------------------|-------------|-------------|-------------|-------------|
| GO:0003013~circulatory system process   | 4 | 2.75E-04    | CALCA, NTS, ADORA2A, DRD2       | 28.80339163 | 0.139182199 | 0.008777277 | 0.399998732 |
| GO:0008015~blood circulation  | 4 | 2.75E-04    | CALCA, NTS, ADORA2A, DRD2       | 28.80339163 | 0.139182199 | 0.008777277 | 0.399998732 |
| GO:0031644~regulation of neurological system process  | 4 | 2.90E-04    | CALCA, ADORA2A, DRD2, DRD1A     | 28.29359708 | 0.146125621 | 0.008737779 | 0.42156818  |
| GO:0019932~second-messenger-mediated signaling  | 4 | 3.29E-04    | CALCA, ADORA2A, DRD2, DRD1A     | 27.09471585 | 0.164266325 | 0.00940003  | 0.478737417 |
| GO:0007270~nerve-nerve synaptic transmission  | 3 | 4.83E-04    | ADORA2A, DRD2, DRD1A            | 85.63865546 | 0.231357137 | 0.013070274 | 0.701210284 |
| GO:0043279~response to alkaloid   | 3 | 5.55E-04    | ADORA2A, DRD2, DRD1A            | 79.92941176 | 0.260959331 | 0.014296925 | 0.8054474   |
| GO:0010578~regulation of adenylate cyclase activity involved in G-protein signaling         | 3 | 6.32E-04    | CALCA, ADORA2A, DRD1A           | 74.93382353 | 0.291317913 | 0.015530334 | 0.916656665 |
| GO:0007189~activation of adenylate cyclase activity by G-protein signaling pathway          | 3 | 6.32E-04    | CALCA, ADORA2A, DRD1A           | 74.93382353 | 0.291317913 | 0.015530334 | 0.916656665 |
| GO:0010579~positive regulation of adenylate cyclase activity by G-protein signaling pathway | 3 | 6.32E-04    | CALCA, ADORA2A, DRD1A           | 74.93382353 | 0.291317913 | 0.015530334 | 0.916656665 |
| GO:0030182~neuron differentiation   | 5 | 0.001006849 | GSX2, ADORA2A, DRD2, EN2, DRD1A | 10.01621701 | 0.422478078 | 0.023587317 | 1.457478185 |
| GO:0007190~activation of adenylate cyclase activity   | 3 | 0.001037799 | CALCA, ADORA2A, DRD1A           | 58.48493544 | 0.432147728 | 0.023303105 | 1.501965506 |
| GO:0031281~positive regulation of cyclase   | 3 | 0.00108894  | CALCA, ADORA2A, DRD1A           | 57.09243697 | 0.44777305  | 0.023471992 | 1.575435653 |



|  |   |                 |                       |             |             |             |             |
|--|---|-----------------|-----------------------|-------------|-------------|-------------|-------------|
| activity   |   | 1               |                       |             |             |             |             |
| GO:0045762~positive regulation of adenylate cyclase activity | 3 | 0.00108894<br>1 | CALCA, ADORA2A, DRD1A | 57.09243697 | 0.44777305  | 0.023471992 | 1.575435653 |
| GO:0051349~positive regulation of lyase activity             | 3 | 0.00108894<br>1 | CALCA, ADORA2A, DRD1A | 57.09243697 | 0.44777305  | 0.023471992 | 1.575435653 |
| GO:0014070~response to organic cyclic substance              | 3 | 0.00108894<br>1 | ADORA2A, DRD2, DRD1A  | 57.09243697 | 0.44777305  | 0.023471992 | 1.575435653 |
| GO:0048167~regulation of synaptic plasticity                 | 3 | 0.00142076<br>4 | ADORA2A, DRD2, DRD1A  | 49.95588235 | 0.539234912 | 0.029362857 | 2.050888783 |
| GO:0050880~regulation of blood vessel size                   | 3 | 0.00142076<br>4 | CALCA, NTS, ADORA2A   | 49.95588235 | 0.539234912 | 0.029362857 | 2.050888783 |
| GO:0035150~regulation of tube size                           | 3 | 0.00142076<br>4 | CALCA, NTS, ADORA2A   | 49.95588235 | 0.539234912 | 0.029362857 | 2.050888783 |
| GO:0003018~vascular process in circulatory system            | 3 | 0.00154082<br>3 | CALCA, NTS, ADORA2A   | 47.95764706 | 0.568460573 | 0.030646372 | 2.222388572 |
| GO:0008227~amine receptor activity                           | 3 | 0.00158539<br>8 | DRD2, HTR1D, DRD1A    | 47.00943396 | 0.1164074   | 0.1164074   | 1.664328376 |
| GO:0043176~amine binding                                     | 3 | 0.00209448      | DRD2, HTR1D, DRD1A    | 40.8442623  | 0.15086814  | 0.07851649  | 2.193410917 |
| GO:0048871~multicellular organismal                          | 3 | 0.00308096      | TEX15, DRD2, DRD1A    | 33.77299089 | 0.813946171 | 0.05829329  | 4.397755673 |

|  |   |                 |                                    |             |             |             |             |
|--|---|-----------------|------------------------------------|-------------|-------------|-------------|-------------|
| homeostasis  |   | 7               |                                    |             |             |             |             |
| GO:0021537~telencephalon development                                   | 3 | 0.00316682<br>3 | GSX2, DRD2, DRD1A                  | 33.30392157 | 0.822477345 | 0.057867036 | 4.517684957 |
| GO:0043085~positive regulation of catalytic activity                   | 4 | 0.00325975      | CALCA, ADORA2A, DRD2, DRD1A        | 12.24971828 | 0.831271726 | 0.05759063  | 4.647334979 |
| GO:0051968~positive regulation of synaptic transmission, glutamatergic | 2 | 0.00352863      | ADORA2A, DRD1A                     | 532.8627451 | 0.854343532 | 0.060253671 | 5.021547078 |
| GO:0042592~homeostatic process   | 5 | 0.00406599<br>2 | CALCA, TEX15, ADORA2A, DRD2, DRD1A | 6.843271555 | 0.891443327 | 0.067037331 | 5.765322123 |
| GO:0048666~neuron development  | 4 | 0.00446945<br>9 | ADORA2A, DRD2, EN2, DRD1A          | 10.94923449 | 0.91295367  | 0.071309023 | 6.320200347 |
| GO:0050801~ion homeostasis   | 4 | 0.00451244<br>5 | CALCA, ADORA2A, DRD2, DRD1A        | 10.91186509 | 0.914978249 | 0.0699301   | 6.379139055 |
| GO:0021853~cerebral cortex GABAergic interneuron migration             | 2 | 0.00470224<br>4 | DRD2, DRD1A                        | 399.6470588 | 0.923370037 | 0.070764753 | 6.638958126 |
| GO:0021894~cerebral cortex GABAergic interneuron development           | 2 | 0.00470224<br>4 | DRD2, DRD1A                        | 399.6470588 | 0.923370037 | 0.070764753 | 6.638958126 |
| GO:0021830~interneuron migration from the subpallium to the cortex     | 2 | 0.00470224<br>4 | DRD2, DRD1A                        | 399.6470588 | 0.923370037 | 0.070764753 | 6.638958126 |

|  |   |                 |                             |             |             |             |             |
|--|---|-----------------|-----------------------------|-------------|-------------|-------------|-------------|
| GO:0060158~activation of phospholipase C activity by dopamine receptor signaling pathway | 2 | 0.00470224<br>4 | DRD2, DRD1A                 | 399.6470588 | 0.923370037 | 0.070764753 | 6.638958126 |
| GO:0044093~positive regulation of molecular function                                     | 4 | 0.00509447<br>4 | CALCA, ADORA2A, DRD2, DRD1A | 10.44828912 | 0.938183491 | 0.07440805  | 7.173763574 |
| GO:0004952~dopamine receptor activity  | 2 | 0.00563230<br>8 | DRD2, DRD1A                 | 332.2       | 0.356325337 | 0.136579933 | 5.799609945 |
| GO:0021826~substrate-independent telencephalic tangential migration                      | 2 | 0.00587456<br>2 | DRD2, DRD1A                 | 319.7176471 | 0.959686833 | 0.083126594 | 8.228941996 |
| GO:0003091~renal water homeostasis   | 2 | 0.00587456<br>2 | ADORA2A, DRD2               | 319.7176471 | 0.959686833 | 0.083126594 | 8.228941996 |
| GO:0021843~substrate-independent telencephalic tangential interneuron migration          | 2 | 0.00587456<br>2 | DRD2, DRD1A                 | 319.7176471 | 0.959686833 | 0.083126594 | 8.228941996 |
| GO:0030146~diuresis  | 2 | 0.00587456<br>2 | ADORA2A, DRD2               | 319.7176471 | 0.959686833 | 0.083126594 | 8.228941996 |
| GO:0030147~natriuresis   | 2 | 0.00587456<br>2 | ADORA2A, DRD2               | 319.7176471 | 0.959686833 | 0.083126594 | 8.228941996 |
| GO:0051590~positive regulation of neurotransmitter transport                             | 2 | 0.00587456<br>2 | ADORA2A, DRD2               | 319.7176471 | 0.959686833 | 0.083126594 | 8.228941996 |
| GO:0050804~regulation of synaptic transmission   | 3 | 0.00601635      | ADORA2A, DRD2, DRD1A        | 23.97882353 | 0.962702102 | 0.082908335 | 8.419537336 |

|  |   |             |                      |             |             |             |             |
|--|---|-------------|----------------------|-------------|-------------|-------------|-------------|
|  |   | 8           |                      |             |             |             |             |
| GO:0051241~negative regulation of multicellular organismal process | 3 | 0.006016358 | CALCA, DRD2, DRD1A   | 23.97882353 | 0.962702102 | 0.082908335 | 8.419537336 |
| GO:0030424~axon  | 3 | 0.006173201 | CALCA, ADORA2A, DRD2 | 23.37196262 | 0.275302783 | 0.275302783 | 5.838852183 |
| GO:0032101~regulation of response to external stimulus             | 3 | 0.006371524 | CALCA, ADORA2A, DRD2 | 23.28041119 | 0.969303003 | 0.08544972  | 8.895317197 |
| GO:0051969~regulation of transmission of nerve impulse             | 3 | 0.006859709 | ADORA2A, DRD2, DRD1A | 22.41011545 | 0.976515699 | 0.089522032 | 9.545531972 |
| GO:0014002~astrocyte development                                   | 2 | 0.007045585 | ADORA2A, DRD1A       | 266.4313725 | 0.978793223 | 0.089704682 | 9.791961814 |
| GO:0050891~multicellular organismal water homeostasis              | 2 | 0.007045585 | ADORA2A, DRD2        | 266.4313725 | 0.978793223 | 0.089704682 | 9.791961814 |
| GO:0040012~regulation of locomotion                                | 3 | 0.00723674  | ADORA2A, DRD2, DRD1A | 21.79893048 | 0.980905658 | 0.089941816 | 10.0447387  |
| GO:0035240~dopamine binding  | 2 | 0.007876929 | DRD2, DRD1A          | 237.2857143 | 0.460349228 | 0.142906502 | 8.024735557 |
| GO:0021892~cerebral cortex GABAergic interneuron differentiation   | 2 | 0.008215315 | DRD2, DRD1A          | 228.3697479 | 0.988844685 | 0.099274203 | 11.32847292 |
| GO:0014821~phasic smooth muscle contraction                        | 2 | 0.00821531  | DRD2, DRD1A          | 228.3697479 | 0.988844685 | 0.099274203 | 11.32847292 |

|  |   |                 |                             |             |             |             |             |
|--|---|-----------------|-----------------------------|-------------|-------------|-------------|-------------|
|  |   | 5               |                             |             |             |             |             |
| GO:0030432~peristalsis                               | 2 | 0.00821531<br>5 | DRD2, DRD1A                 | 228.3697479 | 0.988844685 | 0.099274203 | 11.32847292 |
| GO:0001963~synaptic transmission,<br>dopaminergic    | 2 | 0.00821531<br>5 | ADORA2A, DRD1A              | 228.3697479 | 0.988844685 | 0.099274203 | 11.32847292 |
| GO:0048878~chemical homeostasis                      | 4 | 0.00829959<br>8 | CALCA, ADORA2A, DRD2, DRD1A | 8.759387591 | 0.989349584 | 0.098081236 | 11.43823797 |
| GO:0048708~astrocyte differentiation                 | 2 | 0.00938375<br>2 | ADORA2A, DRD1A              | 199.8235294 | 0.994132292 | 0.107906426 | 12.83892299 |
| GO:0051954~positive regulation of amine<br>transport | 2 | 0.00938375<br>2 | ADORA2A, DRD2               | 199.8235294 | 0.994132292 | 0.107906426 | 12.83892299 |
| GO:0048148~behavioral response to cocaine            | 2 | 0.00938375<br>2 | DRD2, DRD1A                 | 199.8235294 | 0.994132292 | 0.107906426 | 12.83892299 |
| GO:0060134~prepulse inhibition                       | 2 | 0.00938375<br>2 | ADORA2A, DRD2               | 199.8235294 | 0.994132292 | 0.107906426 | 12.83892299 |
| GO:0007625~grooming behavior                         | 2 | 0.0105509       | DRD2, DRD1A                 | 177.620915  | 0.996913725 | 0.118093607 | 14.32375219 |
| GO:0007610~behavior                                  | 4 | 0.01102521<br>3 | CALCA, ADORA2A, DRD2, DRD1A | 7.89426289  | 0.997623461 | 0.120635275 | 14.92040658 |
| GO:0030104~water homeostasis                         | 2 | 0.01171675      | ADORA2A, DRD2               | 159.8588235 | 0.99837677  | 0.125252079 | 15.78339327 |

|   |   |                 |               |             |             |             |             |
|---|---|-----------------|---------------|-------------|-------------|-------------|-------------|
|   |   | 8               |               |             |             |             |             |
| GO:0043178~alcohol binding                                | 2 | 0.01235199<br>3 | DRD2, DRD1A   | 151         | 0.62071037  | 0.17625234  | 12.31949552 |
| GO:0032228~regulation of synaptic transmission, GABAergic | 2 | 0.01288132<br>8 | ADORA2A, DRD2 | 145.3262032 | 0.9991463   | 0.134287731 | 17.21827169 |
| GO:0021895~cerebral cortex neuron differentiation         | 2 | 0.01404461<br>1 | DRD2, DRD1A   | 133.2156863 | 0.999551038 | 0.142874948 | 18.62880578 |
| GO:0050433~regulation of catecholamine secretion          | 2 | 0.01404461<br>1 | ADORA2A, DRD2 | 133.2156863 | 0.999551038 | 0.142874948 | 18.62880578 |
| GO:0042220~response to cocaine                            | 2 | 0.01520660<br>9 | DRD2, DRD1A   | 122.9683258 | 0.999763901 | 0.151045955 | 20.01540681 |
| GO:0050805~negative regulation of synaptic transmission   | 2 | 0.01520660<br>9 | DRD2, DRD1A   | 122.9683258 | 0.999763901 | 0.151045955 | 20.01540681 |
| GO:0021544~subpallium development                         | 2 | 0.01520660<br>9 | GSX2, DRD1A   | 122.9683258 | 0.999763901 | 0.151045955 | 20.01540681 |
| GO:0007589~body fluid secretion                           | 2 | 0.01520660<br>9 | ADORA2A, DRD2 | 122.9683258 | 0.999763901 | 0.151045955 | 20.01540681 |
| GO:0014073~response to tropane                            | 2 | 0.01520660<br>9 | DRD2, DRD1A   | 122.9683258 | 0.999763901 | 0.151045955 | 20.01540681 |

|   |   |             |  |             |             |             |             |
|---|---|-------------|--|-------------|-------------|-------------|-------------|
| GO:0051240~positive regulation of multicellular organismal process                                | 3 | 0.015370129 | ADORA2A, DRD2, DRD1A                           | 14.71093468 | 0.99978433  | 0.149849256 | 20.2087572  |
| GO:0007186~G-protein coupled receptor protein signaling pathway                                   | 7 | 0.016006943 | CALCA, ADORA2A, DRD2, RGS9, HTR1D, NMBR, DRD1A | 2.980851797 | 0.999848414 | 0.152895564 | 20.95760358 |
| GO:0030900~forebrain development  | 3 | 0.016092075 | GSX2, DRD2, DRD1A                              | 14.35857696 | 0.999855396 | 0.151030236 | 21.05721501 |
| GO:0051970~negative regulation of transmission of nerve impulse                                   | 2 | 0.016367323 | DRD2, DRD1A                                    | 114.1848739 | 0.999875847 | 0.150856621 | 21.37847916 |
| GO:0001976~neurological system process involved in regulation of systemic arterial blood pressure | 2 | 0.016367323 | CALCA, DRD2                                    | 114.1848739 | 0.999875847 | 0.150856621 | 21.37847916 |
| GO:0007268~synaptic transmission  | 3 | 0.018151656 | ADORA2A, DRD2, DRD1A                           | 13.47124917 | 0.999953847 | 0.163289765 | 23.43175947 |
| GO:0002027~regulation of heart rate   | 2 | 0.018684905 | CALCA, DRD2                                    | 99.91176471 | 0.999965674 | 0.165017129 | 24.03562132 |
| GO:0045776~negative regulation of blood pressure  | 2 | 0.018684905 | CALCA, DRD2                                    | 99.91176471 | 0.999965674 | 0.165017129 | 24.03562132 |
| GO:0009719~response to endogenous stimulus  | 3 | 0.019320208 | ADORA2A, DRD2, DRD1A                           | 13.03196931 | 0.999975882 | 0.167498274 | 24.74926043 |

|  |   |                 |                                      |             |             |             |             |
|--|---|-----------------|--------------------------------------|-------------|-------------|-------------|-------------|
| GO:0007242~intracellular signaling cascade           | 5 | 0.01936353<br>4 | CALCA, ADORA2A, DRD2, RGS9,<br>DRD1A | 4.367727419 | 0.999976456 | 0.165248303 | 24.79769984 |
| GO:0010648~negative regulation of cell communication | 3 | 0.01971670<br>2 | DRD2, RGS9, DRD1A                    | 12.89184061 | 0.999980653 | 0.165466591 | 25.19147451 |
| GO:0001964~startle response                          | 2 | 0.01984177<br>5 | ADORA2A, DRD2                        | 94.03460208 | 0.999981952 | 0.163941938 | 25.3304663  |
| GO:0001659~temperature homeostasis                   | 2 | 0.02099736<br>7 | DRD2, DRD1A                          | 88.81045752 | 0.999990511 | 0.170173773 | 26.60333313 |
| GO:0022029~telencephalon cell migration              | 2 | 0.02099736<br>7 | DRD2, DRD1A                          | 88.81045752 | 0.999990511 | 0.170173773 | 26.60333313 |
| GO:0006939~smooth muscle contraction                 | 2 | 0.02099736<br>7 | DRD2, DRD1A                          | 88.81045752 | 0.999990511 | 0.170173773 | 26.60333313 |
| GO:0008306~associative learning                      | 2 | 0.02099736<br>7 | DRD2, DRD1A                          | 88.81045752 | 0.999990511 | 0.170173773 | 26.60333313 |
| GO:0051336~regulation of hydrolase activity          | 3 | 0.02175076<br>6 | ADORA2A, DRD2, DRD1A                 | 12.23409364 | 0.999993763 | 0.173237557 | 27.42227662 |
| GO:0021885~forebrain cell migration                  | 2 | 0.02215168<br>1 | DRD2, DRD1A                          | 84.13622291 | 0.999995012 | 0.173665875 | 27.85459329 |
| GO:0007212~dopamine receptor signaling               | 2 | 0.02330471      | DRD2, DRD1A                          | 79.92941176 | 0.999997378 | 0.17939548  | 29.08461199 |



|   |   |                 |                      |             |             |             |             |
|---|---|-----------------|----------------------|-------------|-------------|-------------|-------------|
| pathway   |   | 9               |                      |             |             |             |             |
| GO:0007588~excretion  | 2 | 0.02445648<br>2 | ADORA2A, DRD2        | 76.1232493  | 0.999998621 | 0.184914105 | 30.2937483  |
| GO:0050806~positive regulation of synaptic transmission         | 2 | 0.02445648<br>2 | ADORA2A, DRD1A       | 76.1232493  | 0.999998621 | 0.184914105 | 30.2937483  |
| GO:0051971~positive regulation of transmission of nerve impulse | 2 | 0.02560697<br>2 | ADORA2A, DRD1A       | 72.6631016  | 0.999999275 | 0.190233097 | 31.48235525 |
| GO:0051588~regulation of neurotransmitter transport             | 2 | 0.02560697<br>2 | ADORA2A, DRD2        | 72.6631016  | 0.999999275 | 0.190233097 | 31.48235525 |
| GO:0021782~glial cell development                               | 2 | 0.02675619      | ADORA2A, DRD1A       | 69.50383632 | 0.999999619 | 0.195363013 | 32.65077992 |
| GO:0033267~axon part  | 2 | 0.02764435<br>6 | CALCA, ADORA2A       | 66.688      | 0.767240591 | 0.517548542 | 23.84238433 |
| GO:0031646~positive regulation of neurological system process   | 2 | 0.02790413<br>7 | ADORA2A, DRD1A       | 66.60784314 | 0.9999998   | 0.200313685 | 33.79936354 |
| GO:0003014~renal system process                                 | 2 | 0.02790413<br>7 | ADORA2A, DRD2        | 66.60784314 | 0.9999998   | 0.200313685 | 33.79936354 |
| GO:0019226~transmission of nerve impulse                        | 3 | 0.02835202<br>7 | ADORA2A, DRD2, DRD1A | 10.61009891 | 0.999999844 | 0.200629265 | 34.24253408 |
| GO:0051952~regulation of amine transport                        | 2 | 0.02905081      | ADORA2A, DRD2        | 63.94352941 | 0.999999895 | 0.202520317 | 34.92844162 |

|   |   |                 |                      |             |             |             |             |
|---|---|-----------------|----------------------|-------------|-------------|-------------|-------------|
|   |   | 4               |                      |             |             |             |             |
| GO:0007200~activation of phospholipase C activity by G-protein coupled receptor protein signaling pathway coupled to IP3 second messenger | 2 | 0.02905081<br>4 | DRD2, DRD1A          | 63.94352941 | 0.999999895 | 0.202520317 | 34.92844162 |
| GO:0043005~neuron projection  | 3 | 0.02979634<br>2 | CALCA, ADORA2A, DRD2 | 10.20734694 | 0.792570178 | 0.408042676 | 25.46424867 |
| GO:0010863~positive regulation of phospholipase C activity  | 2 | 0.03019622<br>3 | DRD2, DRD1A          | 61.4841629  | 0.999999945 | 0.207125773 | 36.038344   |
| GO:0007202~activation of phospholipase C activity   | 2 | 0.03019622<br>3 | DRD2, DRD1A          | 61.4841629  | 0.999999945 | 0.207125773 | 36.038344   |
| GO:0010518~positive regulation of phospholipase activity  | 2 | 0.03019622<br>3 | DRD2, DRD1A          | 61.4841629  | 0.999999945 | 0.207125773 | 36.038344   |
| GO:0060193~positive regulation of lipase activity   | 2 | 0.03134036<br>6 | DRD2, DRD1A          | 59.20697168 | 0.999999971 | 0.211580049 | 37.12939497 |
| GO:0007628~adult walking behavior   | 2 | 0.03134036<br>6 | DRD2, DRD1A          | 59.20697168 | 0.999999971 | 0.211580049 | 37.12939497 |
| GO:0042311~vasodilation   | 2 | 0.03134036<br>6 | CALCA, ADORA2A       | 59.20697168 | 0.999999971 | 0.211580049 | 37.12939497 |

|   |   |                 |                       |             |             |             |             |
|---|---|-----------------|-----------------------|-------------|-------------|-------------|-------------|
| GO:0007626~locomotory behavior                            | 3 | 0.03143536<br>2 | ADORA2A, DRD2, DRD1A  | 10.03298056 | 0.999999972 | 0.20961429  | 37.21919917 |
| GO:0003073~regulation of systemic arterial blood pressure | 2 | 0.03248324<br>3 | CALCA, DRD2           | 57.09243697 | 0.999999985 | 0.213343622 | 38.20191336 |
| GO:0010517~regulation of phospholipase activity           | 2 | 0.03248324<br>3 | DRD2, DRD1A           | 57.09243697 | 0.999999985 | 0.213343622 | 38.20191336 |
| GO:0008542~visual learning                                | 2 | 0.03362485<br>6 | DRD2, DRD1A           | 55.12373225 | 0.999999992 | 0.217508912 | 39.25621264 |
| GO:0009628~response to abiotic stimulus                   | 3 | 0.03439581<br>4 | CALCA, DRD2, DRD1A    | 9.553316147 | 0.999999995 | 0.219434239 | 39.95870265 |
| GO:0007632~visual behavior                                | 2 | 0.03590429<br>3 | DRD2, DRD1A           | 51.56736243 | 0.999999998 | 0.225458612 | 41.31138137 |
| GO:0040013~negative regulation of locomotion              | 2 | 0.03590429<br>3 | ADORA2A, DRD2         | 51.56736243 | 0.999999998 | 0.225458612 | 41.31138137 |
| GO:0006873~cellular ion homeostasis                       | 3 | 0.03694427<br>6 | CALCA, ADORA2A, DRD1A | 9.187288709 | 0.999999999 | 0.228713961 | 42.22736203 |
| GO:0060191~regulation of lipase activity                  | 2 | 0.03704212<br>1 | DRD2, DRD1A           | 49.95588235 | 0.999999999 | 0.22674156  | 42.31285171 |
| GO:0021954~central nervous system neuron                  | 2 | 0.03817869      | DRD2, DRD1A           | 48.44206774 | 0.999999999 | 0.230422413 | 43.29730487 |

|   |   |                 |  |             |   |             |             |
|---|---|-----------------|--|-------------|---|-------------|-------------|
| development   |   |                 |  |             |   |             |             |
| GO:0055082~cellular chemical homeostasis                        | 3 | 0.03877118<br>3 | CALCA, ADORA2A, DRD1A                      | 8.947322212 | 1 | 0.231115812 | 43.80427365 |
| GO:0050877~neurological system process                          | 6 | 0.03900640<br>7 | CALCA, GSX2, ADORA2A, DRD2,<br>RGS9, DRD1A | 2.85292368  | 1 | 0.229915873 | 44.00437033 |
| GO:0032102~negative regulation of response to external stimulus | 2 | 0.04158085<br>5 | ADORA2A, DRD2                              | 44.40522876 | 1 | 0.240845449 | 46.15141638 |
| GO:0033555~multicellular organismal response to stress          | 2 | 0.04271240<br>1 | CALCA, DRD1A                               | 43.20508744 | 1 | 0.244127506 | 47.07063203 |
| GO:0007267~cell-cell signaling                                  | 3 | 0.04473586<br>4 | ADORA2A, DRD2, DRD1A                       | 8.268559838 | 1 | 0.251764537 | 48.67806503 |
| GO:0048015~phosphoinositide-mediated signaling                  | 2 | 0.04609952<br>8 | DRD2, DRD1A                                | 39.96470588 | 1 | 0.255954228 | 49.73558115 |
| GO:0021953~central nervous system neuron differentiation        | 2 | 0.04835136<br>7 | DRD2, DRD1A                                | 38.06162465 | 1 | 0.264298154 | 51.43755523 |

### B. Enriched GO terms of down-regulated DEGs in long-term PFC.

| Term                                   | Count | PValue      | Genes  | Fold Enrichment | Bonferroni  | Benjamini   | FDR         |
|--|-------|-------------|--|-----------------|-------------|-------------|-------------|
| GO:0005833~hemoglobin complex          | 4     | 1.02E-06    | HBA-A2, HBB-BH1, HBB-B2, HBB-Y   | 178.6285714     | 9.68E-05    | 9.68E-05    | 0.00112027  |
| GO:0015671~oxygen transport            | 4     | 4.45E-06    | HBA-A2, HBB-BH1, HBB-B2, HBB-Y   | 114.9090909     | 0.001602047 | 0.001602047 | 0.006116548 |
| GO:0005344~oxygen transporter activity | 4     | 5.12E-06    | HBA-A2, HBB-BH1, HBB-B2, HBB-Y   | 109.8181818     | 7.26E-04    | 7.26E-04    | 0.006050134 |
| GO:0015669~gas transport               | 4     | 7.69E-06    | HBA-A2, HBB-BH1, HBB-B2, HBB-Y   | 97.23076923     | 0.002763341 | 0.001382627 | 0.010556228 |
| GO:0019825~oxygen binding              | 4     | 1.12E-05    | HBA-A2, HBB-BH1, HBB-B2, HBB-Y   | 86.28571429     | 0.001590275 | 7.95E-04    | 0.013256383 |
| GO:0044445~cytosolic part              | 4     | 6.53E-04    | HBA-A2, HBB-BH1, HBB-B2, HBB-Y   | 22.6829932      | 0.060125798 | 0.030528906 | 0.714914919 |
| GO:0020037~heme binding                | 4     | 0.011208585 | HBA-A2, HBB-BH1, HBB-B2, HBB-Y   | 8.388888889     | 0.798225829 | 0.413472304 | 12.48217873 |
| GO:0046906~tetrapyrrole binding        | 4     | 0.012736312 | HBA-A2, HBB-BH1, HBB-B2, HBB-Y   | 8               | 0.838002155 | 0.365579352 | 14.06828514 |
| GO:0043167~ion binding                 | 21    | 0.014007601 | GAL3ST3, CACNA2D1, HBB-BH1, CAR13, S100A8, S100A9, CLCNKA, ANXA1, BRSK1, ATMIN, HBB-Y, GCH1, RNF125, HBA-A2, UMODL1, TRIM9, CH25H, PLA2G12A, ADAMTS1, HBB-B2, KLF1 | 1.612099644     | 0.865089261 | 0.330101038 | 15.36804539 |
| GO:0006955~immune response             | 6     | 0.014494923 | RNF125, CXCL1, H2-Q10, CD8B1, SERPINA3G, PGLYRP1   | 4.025477707     | 0.994785751 | 0.826594084 | 18.17038699 |

|                                    |    |             |   |             |             |             |             |
|------------------------------------|----|-------------|---|-------------|-------------|-------------|-------------|
| GO:0005829~cytosol                 | 6  | 0.015537843 | HBA-A2, HBB-BH1, IRS2, RAPGEF4,<br>HBB-B2, HBB-Y  | 3.904449649 | 0.774104527 | 0.390973988 | 15.81332177 |
| GO:0046872~metal ion binding       | 20 | 0.023904158 | GAL3ST3, CACNA2D1, HBB-BH1,<br>CAR13, S100A8, S100A9, ANXA1,<br>BRSK1, ATMIN, HBB-Y, GCH1,<br>RNF125, HBA-A2, UMODL1, TRIM9,<br>CH25H, PLA2G12A, ADAMTS1,<br>HBB-B2, KLF1 | 1.568831169 | 0.967794527 | 0.435944792 | 24.88734588 |
| GO:0005506~iron ion binding        | 5  | 0.024414559 | HBA-A2, HBB-BH1, CH25H, HBB-B2,<br>HBB-Y  | 4.402332362 | 0.9700998   | 0.394325687 | 25.3506084  |
| GO:0043169~cation binding          | 20 | 0.026232398 | GAL3ST3, CACNA2D1, HBB-BH1,<br>CAR13, S100A8, S100A9, ANXA1,<br>BRSK1, ATMIN, HBB-Y, GCH1,<br>RNF125, HBA-A2, UMODL1, TRIM9,<br>CH25H, PLA2G12A, ADAMTS1,<br>HBB-B2, KLF1 | 1.554697555 | 0.977056714 | 0.376147452 | 26.97939404 |
| GO:0046903~secretion               | 4  | 0.030606673 | TRIM9, CLCNKA, ANXA1, RAPGEF4   | 5.719457014 | 0.999986196 | 0.939045981 | 34.74848849 |
| GO:0045120~pronucleus              | 2  | 0.047861142 | HNRNPL, TAF1  | 39.6952381  | 0.990526128 | 0.688016315 | 41.67260733 |
| GO:0048821~erythrocyte development | 2  | 0.048351367 | HBA-A2, KLF1  | 39.5        | 0.999999982 | 0.971795576 | 49.37130112 |

### C. Enriched GO terms of up-regulated DEGs in long-term hippocampus.

| Term                                   | Count | PValue      | Genes  | Fold Enrichment | Bonferroni  | Benjamini   | FDR         |
|--|-------|-------------|--|-----------------|-------------|-------------|-------------|
| GO:0005576~extracellular region        | 32    | 3.99E-06    | LEPR, ELN, 1500015O10RIK, IL17RE, TRH, SCT, LGALS3BP, CTGF, SOSTDC1, EMID2, LEFTY2, TFF3, SEMA3A, LBP, WNT6, DEFB2, DKKL1, COL8A2, FGFBP1, BMP3, CPA6, KL, IL25, IGF2, CBLN1, SFRP1, TFPI, IGFBP2, MUP8, WFDC2, PON3, BMP6 | 2.358132956     | 5.23E-04    | 5.23E-04    | 0.00465494  |
| GO:0044421~extracellular region part   | 17    | 4.01E-04    | BMP3, LEPR, ELN, IGF2, LGALS3BP, CTGF, SOSTDC1, EMID2, LEFTY2, TFF3, LBP, WNT6, IGFBP2, COL8A2, FGFBP1, PON3, BMP6   | 2.71916494      | 0.051152986 | 0.025912214 | 0.466323116 |
| GO:0005344~oxygen transporter activity | 3     | 0.002892738 | HBB-BH1, NGB, HBB-Y  | 36.24           | 0.519497674 | 0.519497674 | 3.700254518 |
| GO:0015671~oxygen transport            | 3     | 0.003225748 | HBB-BH1, NGB, HBB-Y  | 34.31313131     | 0.974367939 | 0.974367939 | 5.05440823  |
| GO:0051216~cartilage development       | 5     | 0.003316221 | MEF2C, BMP3, MSX1, CTGF, BMP6  | 8.065052232     | 0.976875056 | 0.847931122 | 5.192652979 |
| GO:0005506~iron ion binding            | 9     | 0.004051161 | 1600014K23RIK, HBB-BH1, CYP2C44, CYP4F14, GUCY1B2, NGB, ASPH, SCARA5, HBB-Y  | 3.48664723      | 0.641929489 | 0.401610067 | 5.146283199 |

|  |    |             |   |             |             |             |             |
|--|----|-------------|---|-------------|-------------|-------------|-------------|
| GO:0020037~heme binding                                | 6  | 0.004412109 | HBB-BH1, CYP2C44, CYP4F14, GUCY1B2, NGB, HBB-Y                                  | 5.536666667 | 0.673306645 | 0.311273542 | 5.592732447 |
| GO:0015669~gas transport                               | 3  | 0.004527944 | HBB-BH1, NGB, HBB-Y   | 29.03418803 | 0.994179378 | 0.820117131 | 7.026110527 |
| GO:0019825~oxygen binding                              | 3  | 0.004717005 | HBB-BH1, NGB, HBB-Y   | 28.47428571 | 0.697666886 | 0.258482458 | 5.968340411 |
| GO:0046906~tetrapyrrole binding                        | 6  | 0.005388669 | HBB-BH1, CYP2C44, CYP4F14, GUCY1B2, NGB, HBB-Y                                  | 5.28        | 0.745134647 | 0.239214617 | 6.790914753 |
| GO:0001503~ossification                                | 5  | 0.009770853 | MEF2C, BMP3, CTGF, IGF2, BMP6   | 5.934661076 | 0.999985402 | 0.938188046 | 14.58269043 |
| GO:0043176~amine binding                               | 4  | 0.010565074 | FOLR2, FOLR1, HTR1D, DRD1A  | 8.713442623 | 0.931927633 | 0.36100841  | 12.91099295 |
| GO:0009986~cell surface                                | 8  | 0.011128009 | KLRC2, COL23A1, SLC6A2, H2-Q1, VPBEB1, CLEC2D, SCARA5, FGFBP1                   | 3.247265054 | 0.769139315 | 0.38654413  | 12.23394077 |
| GO:0009891~positive regulation of biosynthetic process | 11 | 0.012341463 | MEF2C, HSP90AB1, BMP3, TCF21, MSX1, HES5, ADORA2A, NLRP12, CENPK, KAT5, CITED4  | 2.484673183 | 0.999999234 | 0.940182643 | 18.07355989 |
| GO:0060348~bone development                            | 5  | 0.014054577 | MEF2C, BMP3, CTGF, IGF2, BMP6   | 5.331136221 | 0.999999893 | 0.931104099 | 20.32518162 |
| GO:0009628~response to abiotic stimulus                | 7  | 0.014364863 | ARPP21, BRCA2, TRPV4, PCDH15, DRD1A, SCARA5, SLC14A2                            | 3.508779696 | 0.999999925 | 0.904055351 | 20.72674403 |
| GO:0005886~plasma membrane                             | 34 | 0.016359916 | KLRC2, CLDN9, ECEL1, ADORA2A, SLC6A2, TACR1, LEPR, PRSS41, F2RL1, VPBEB1, AQP1, | 1.448474648 | 0.884775567 | 0.417378986 | 17.49876631 |



|   |    |             |   |             |             |             |             |
|---|----|-------------|---|-------------|-------------|-------------|-------------|
|   |    |             | GPR88, VMN1R208, FOLR2, FOLR1, KRT8, CAMK2D, CLEC2D, TRPV4, HTR1D, FGFBP1, COL23A1, CNTN5, KL, AK1, H2-Q1, PCDH15, CBLN1, GABRR1, VMN1R202, OTOF, PERP, DRD1A, SCARA5 |             |             |             |             |
| GO:0019838~growth factor binding              | 4  | 0.016511706 | KL, CTGF, IGFBP2, FGFBP1  | 7.382222222 | 0.98518825  | 0.452154559 | 19.48280213 |
| GO:0010033~response to organic substance      | 10 | 0.018084406 | IRAK1, MSX1, ADH1, ADORA2A, LEPR, VMN1R202, LBP, TRH, DRD1A, VMN1R208   | 2.491382472 | 0.999999999 | 0.924749085 | 25.39506111 |
| GO:0007628~adult walking behavior             | 3  | 0.018968627 | PCDH15, TRH, DRD1A  | 13.97942387 | 1           | 0.910454266 | 26.46624917 |
| GO:0048608~reproductive structure development | 5  | 0.019375831 | TCF21, COL9A3, SFRP1, LEPR, BRCA2   | 4.839031339 | 1           | 0.891258825 | 26.95468997 |
| GO:0005615~extracellular space                | 10 | 0.020999042 | BMP3, LEPR, SOSTDC1, LEFTY2, IGF2, LBP, IGFBP2, FGFBP1, PON3, BMP6  | 2.422739339 | 0.937971926 | 0.426520814 | 21.92383832 |
| GO:0008083~growth factor activity             | 5  | 0.021058753 | BMP3, CTGF, LEFTY2, IGF2, BMP6  | 4.712056738 | 0.995414077 | 0.489872954 | 24.19560034 |
| GO:0051173~positive regulation of nitrogen    | 10 | 0.022863155 | MEF2C, HSP90AB1, BMP3, TCF21, MSX1, HES5, ADORA2A, CENPK, KAT5, CITED4  | 2.391916631 | 1           | 0.907850711 | 31.01489868 |

|  |    |             |  |             |   |             |             |
|--|----|-------------|--|-------------|---|-------------|-------------|
| compound metabolic process   |    |             |  |             |   |             |             |
| GO:0043279~response to alkaloid  | 3  | 0.023152265 | ADORA2A, LEPR, DRD1A                                     | 12.58148148 | 1 | 0.890695111 | 31.34182393 |
| GO:0006620~posttranslational protein targeting to membrane   | 2  | 0.023439958 | FOLR2, FOLR1   | 83.87654321 | 1 | 0.873691809 | 31.66570425 |
| GO:0006978~DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator | 2  | 0.023439958 | BRCA2, KAT5  | 83.87654321 | 1 | 0.873691809 | 31.66570425 |
| GO:0051968~positive regulation of synaptic transmission, glutamatergic   | 2  | 0.023439958 | ADORA2A, DRD1A   | 83.87654321 | 1 | 0.873691809 | 31.66570425 |
| GO:0042772~DNA damage response, signal transduction resulting in transcription   | 2  | 0.023439958 | BRCA2, KAT5  | 83.87654321 | 1 | 0.873691809 | 31.66570425 |
| GO:0006952~defense response  | 9  | 0.02503815  | IRAK1, H2-Q1, IL25, CLEC2D, C1S, LBP, DEFB2, DRD1A, BMP6 | 2.527529762 | 1 | 0.871767712 | 33.43899478 |
| GO:0031328~positive  | 10 | 0.029964084 | MEF2C, HSP90AB1, BMP3, TCF21, MSX1, HES5,                | 2.279253892 | 1 | 0.899732829 | 38.63698755 |

|  |   |             |  |             |             |             |             |
|--|---|-------------|--|-------------|-------------|-------------|-------------|
| regulation of cellular biosynthetic process            |   |             | ADORA2A, CENPK, KAT5, CITED4                         |             |             |             |             |
| GO:0005578~proteinaceous extracellular matrix          | 7 | 0.031766344 | LGALS3BP, CTGF, ELN, EMID2, TFF3, WNT6, COL8A2       | 2.917891789 | 0.9854319   | 0.505802569 | 31.37070461 |
| GO:0033555~multicellular organismal response to stress | 3 | 0.0342113   | SLC6A2, TACR1, DRD1A                                 | 10.2012012  | 1           | 0.915175711 | 42.81069386 |
| GO:0008517~folic acid transporter activity             | 2 | 0.036706144 | FOLR2, FOLR1   | 53.152      | 0.999922201 | 0.650504533 | 38.53679334 |
| GO:0030534~adult behavior                              | 4 | 0.036987651 | ADH1, PCDH15, TRH, DRD1A                             | 5.411389885 | 1           | 0.919062734 | 45.39347642 |
| GO:0031012~extracellular matrix                        | 7 | 0.037440215 | LGALS3BP, CTGF, ELN, EMID2, TFF3, WNT6, COL8A2       | 2.804575603 | 0.993254247 | 0.510377359 | 35.91678006 |
| GO:0032535~regulation of cellular component size       | 5 | 0.038316014 | ELN, LEFTY2, VPREB1, SEMA3A, VILL                    | 3.907292386 | 1           | 0.914682093 | 46.59015882 |
| GO:0007626~locomotory behavior                         | 6 | 0.040486518 | ADORA2A, PCDH15, SEMA3A, LBP, TRH, DRD1A             | 3.158530916 | 1           | 0.915134151 | 48.49272493 |
| GO:0007610~behavior                                    | 8 | 0.040770218 | ADH1, ADORA2A, LEPR, PCDH15, SEMA3A, LBP, TRH, DRD1A | 2.48523091  | 1           | 0.905590764 | 48.73665393 |
| GO:0014070~response to organic cyclic substance        | 3 | 0.043125482 | ADORA2A, LEPR, DRD1A                                 | 8.986772487 | 1           | 0.9074941   | 50.72031945 |

|   |   |             |  |             |   |             |             |
|---|---|-------------|--|-------------|---|-------------|-------------|
| GO:0014002~astrocyte development  | 2 | 0.046335499 | ADORA2A, DRD1A   | 41.9382716  | 1 | 0.913316249 | 53.30818228 |
| GO:0045935~positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 9 | 0.047984744 | MEF2C, BMP3, TCF21, MSX1, HES5, ADORA2A, CENPK, KAT5, CITED4 | 2.220261438 | 1 | 0.911477878 | 54.5876778  |

#### D. Enriched GO terms of down-regulated DEGs in long-term hippocampus.

| Term  | Count | PValue      | Genes  | Fold Enrichment | Bonferroni  | Benjamini   | FDR         |
|---|-------|-------------|--|-----------------|-------------|-------------|-------------|
| GO:0019911~structural constituent of myelin sheath      | 3     | 9.15E-05    | PLP1, MOBP, MBP                                  | 177.1733333     | 0.015067898 | 0.015067898 | 0.111070841 |
| GO:0043209~myelin sheath                                | 3     | 8.46E-04    | PLP1, ERMN, MBP                                  | 66.04225352     | 0.093556146 | 0.093556146 | 0.961422394 |
| GO:0042552~myelination                                  | 4     | 0.001139563 | PLP1, UGT8A, NKX6-2, MBP                         | 19.07757108     | 0.686029392 | 0.686029392 | 1.788952175 |
| GO:0051094~positive regulation of developmental process | 7     | 0.001243182 | FGFR2, EPC1, WNT7B, LECT1, NKX6-2, INPP5D, FOXP3 | 5.772302464     | 0.717438336 | 0.468434704 | 1.950123621 |
| GO:0008366~axon ensheathment                            | 4     | 0.001329641 | PLP1, UGT8A, NKX6-2, MBP                         | 18.0992341      | 0.741229672 | 0.362757364 | 2.084414842 |
| GO:0007272~ensheathment of neurons                      | 4     | 0.001329641 | PLP1, UGT8A, NKX6-2, MBP                         | 18.0992341      | 0.741229672 | 0.362757364 | 2.084414842 |
| GO:0019228~regulation of action potential in neuron     | 4     | 0.002015502 | PLP1, UGT8A, NKX6-2, MBP                         | 15.68600289     | 0.871241503 | 0.400976343 | 3.14362518  |
| GO:0006917~induction of apoptosis                       | 6     | 0.002415794 | PLEKHF1, PTPN6, MAL, TRAF6, MYC, GCH1            | 6.340150867     | 0.914344059 | 0.388281665 | 3.756846199 |
| GO:0012502~induction of programmed cell death           | 6     | 0.002415794 | PLEKHF1, PTPN6, MAL, TRAF6, MYC, GCH1            | 6.340150867     | 0.914344059 | 0.388281665 | 3.756846199 |
| GO:0043065~positive regulation of apoptosis             | 7     | 0.002619506 | PLEKHF1, PTPN6, MAL, INPP5D, TRAF6, MYC, GCH1    | 4.980938416     | 0.930394413 | 0.358631907 | 4.067521052 |
| GO:0043068~positive regulation of                       | 7     | 0.002726187 | PLEKHF1, PTPN6, MAL, INPP5D,                     | 4.941090909     | 0.937562458 | 0.327146016 | 4.229841506 |

|  |    |             |  |             |             |             |             |
|--|----|-------------|--|-------------|-------------|-------------|-------------|
| programmed cell death                          |    |             | TRAF6, MYC, GCH1   |             |             |             |             |
| GO:0010942~positive regulation of cell death   | 7  | 0.002836104 | PLEKHF1, PTPN6, MAL, INPP5D, TRAF6, MYC, GCH1                              | 4.901875902 | 0.944177333 | 0.302809721 | 4.396816326 |
| GO:0001508~regulation of action potential      | 4  | 0.003398575 | PLP1, UGT8A, NKX6-2, MBP   | 13.07166907 | 0.968533553 | 0.319082981 | 5.247009335 |
| GO:0042981~regulation of apoptosis             | 10 | 0.003607006 | PLEKHF1, PTPN6, MITF, HSPA1A, MAL, HSPA1B, INPP5D, TRAF6, MYC, TIMP1, GCH1 | 3.19109462  | 0.974557736 | 0.307283432 | 5.560256221 |
| GO:0043067~regulation of programmed cell death | 10 | 0.003918084 | PLEKHF1, PTPN6, MITF, HSPA1A, MAL, HSPA1B, INPP5D, TRAF6, MYC, TIMP1, GCH1 | 3.151205937 | 0.981474225 | 0.304134788 | 6.025965396 |
| GO:0010941~regulation of cell death            | 10 | 0.004057706 | PLEKHF1, PTPN6, MITF, HSPA1A, MAL, HSPA1B, INPP5D, TRAF6, MYC, TIMP1, GCH1 | 3.134414431 | 0.983933458 | 0.291249245 | 6.234290913 |
| GO:0006955~immune response                     | 9  | 0.004699487 | CXCL1, PTPN6, CCL3, CXCL5, H2-M2, INPP5D, CLEC7A, TRAF6, FOXP3             | 3.371991066 | 0.991653673 | 0.307985764 | 7.18631872  |
| GO:0048709~oligodendrocyte differentiation     | 3  | 0.005495524 | SOX10, PLP1, NKX6-2  | 26.47012987 | 0.996297885 | 0.329624942 | 8.354590237 |

|  |   |             |  |             |             |             |             |
|--|---|-------------|--|-------------|-------------|-------------|-------------|
| GO:0044092~negative regulation of molecular function                         | 5 | 0.006365479 | OPRM1, PTPN6, HSPA1A, HSPA1B, FOXP3, MYC                             | 6.68437623  | 0.998478408 | 0.3511367   | 9.615582497 |
| GO:0050777~negative regulation of immune response                            | 3 | 0.009198954 | PTPN6, INPP5D, FOXP3   | 20.36163836 | 0.999916394 | 0.443916529 | 13.6109131  |
| GO:0007626~locomotory behavior   | 6 | 0.010839363 | OPRM1, CCL3, CXCL5, S100A8, S100A9, CNP                              | 4.430147259 | 0.999984473 | 0.478657374 | 15.84771274 |
| GO:0043565~sequence-specific DNA binding                                     | 9 | 0.011910471 | MAFF, SOX10, RHOX3A, NKX6-2, HOXC5, MITF, EN2, FOXP3, MYC            | 2.867913669 | 0.863168755 | 0.630092923 | 13.54881356 |
| GO:0003705~RNA polymerase II transcription factor activity, enhancer binding | 3 | 0.012033263 | SOX10, MITF, FOXP3   | 17.71733333 | 0.865962716 | 0.488229549 | 13.67926423 |
| GO:0032675~regulation of interleukin-6 production                            | 3 | 0.013739145 | INPP5D, TRAF6, FOXP3   | 16.54383117 | 0.999999214 | 0.541994937 | 19.66957366 |
| GO:0032880~regulation of protein localization                                | 4 | 0.013949649 | SGK1, RABGAP1L, TRAF6, FOXP3   | 7.843001443 | 0.999999367 | 0.528195606 | 19.94058533 |
| GO:0042592~homeostatic process   | 9 | 0.016070021 | SGK1, PLP1, UGT8A, NKX6-2, IKBKKG, HSPA1A, HSPA1B, FOXP3, TIMP1, MBP | 2.719533891 | 0.999999929 | 0.560882222 | 22.62308763 |
| GO:0050672~negative regulation of  | 3 | 0.016304793 | PTPN6, INPP5D, FOXP3   | 15.1257885  | 0.999999944 | 0.548573684 | 22.91486543 |

|   |   |             |                                      |             |             |             |             |
|---|---|-------------|--------------------------------------|-------------|-------------|-------------|-------------|
| lymphocyte proliferation  |   |             |                                      |             |             |             |             |
| GO:0070664~negative regulation of leukocyte proliferation                     | 3 | 0.016304793 | PTPN6, INPP5D, FOXP3                 | 15.1257885  | 0.999999944 | 0.548573684 | 22.91486543 |
| GO:0032945~negative regulation of mononuclear cell proliferation              | 3 | 0.016304793 | PTPN6, INPP5D, FOXP3                 | 15.1257885  | 0.999999944 | 0.548573684 | 22.91486543 |
| GO:0045597~positive regulation of cell differentiation                        | 5 | 0.016627626 | EPC1, WNT7B, NKX6-2, INPP5D, FOXP3   | 5.041929499 | 0.999999996 | 0.538996559 | 23.3144034  |
| GO:0033269~internode region of axon   | 2 | 0.01670211  | ERMN, MBP                            | 117.4084507 | 0.858266518 | 0.623524925 | 17.48257915 |
| GO:0008009~chemokine activity   | 3 | 0.018898819 | CXCL1, CCL3, CXCL5                   | 13.98736842 | 0.95787979  | 0.546974517 | 20.69214525 |
| GO:0042379~chemokine receptor binding   | 3 | 0.019849456 | CXCL1, CCL3, CXCL5                   | 13.62871795 | 0.964140657 | 0.48605048  | 21.62084744 |
| GO:0001501~skeletal system development  | 6 | 0.021618812 | FGFR2, LECT1, HOXC5, TRAF6, MOG, MYC | 3.715105947 | 1           | 0.619192614 | 29.24987238 |
| GO:0002429~immune response-activating cell surface receptor signaling pathway | 3 | 0.021992292 | PTPN6, CLEC7A, FOXP3                 | 12.91225847 | 1           | 0.609917535 | 29.67624013 |
| GO:0022010~myelination in the central nervous system                          | 2 | 0.022188108 | PLP1, NKX6-2                         | 88.23376623 | 1           | 0.598231404 | 29.89882307 |
| GO:0032291~ensheathment of axons in   | 2 | 0.022188108 | PLP1, NKX6-2                         | 88.23376623 | 1           | 0.598231404 | 29.89882307 |



|   |    |             |   |             |             |             |             |
|---|----|-------------|---|-------------|-------------|-------------|-------------|
| the central nervous system  |    |             |   |             |             |             |             |
| GO:0010605~negative regulation of macromolecule metabolic process             | 8  | 0.022817542 | EPC1, PTPN6, RHOX3A, NKX6-2, ZFP639, INPP5D, FOXP3, MYC           | 2.790000513 | 1           | 0.594230203 | 30.60983168 |
| GO:0042330~taxis  | 4  | 0.023125139 | CCL3, CXCL5, S100A8, S100A9                                       | 6.475872751 | 1           | 0.585387084 | 30.95483103 |
| GO:0006935~chemotaxis   | 4  | 0.023125139 | CCL3, CXCL5, S100A8, S100A9                                       | 6.475872751 | 1           | 0.585387084 | 30.95483103 |
| GO:0002768~immune response-regulating cell surface receptor signaling pathway | 3  | 0.0251007   | PTPN6, CLEC7A, FOXP3  | 12.03187721 | 1           | 0.60244524  | 33.13259203 |
| GO:0003700~transcription factor activity                                      | 10 | 0.027844318 | MAFF, SOX10, RHOX3A, NKX6-2, HOXC5, MITF, ZFP639, EN2, FOXP3, MYC | 2.283161512 | 0.990792411 | 0.54218398  | 29.04538389 |
| GO:0045892~negative regulation of transcription, DNA-dependent                | 6  | 0.028972384 | EPC1, RHOX3A, NKX6-2, ZFP639, FOXP3, MYC                          | 3.437679204 | 1           | 0.643002599 | 37.21519556 |
| GO:0042391~regulation of membrane potential                                   | 4  | 0.028998166 | PLP1, UGT8A, NKX6-2, MBP  | 5.931681764 | 1           | 0.630864601 | 37.24158207 |
| GO:0010558~negative regulation of macromolecule biosynthetic process          | 7  | 0.029344063 | EPC1, RHOX3A, NKX6-2, ZFP639, INPP5D, FOXP3, MYC                  | 2.955197912 | 1           | 0.623230152 | 37.5945848  |
| GO:0002757~immune response-activating signal transduction                     | 3  | 0.029505104 | PTPN6, CLEC7A, FOXP3  | 11.02922078 | 1           | 0.613601108 | 37.75829874 |

|   |   |             |  |             |             |             |             |
|---|---|-------------|--|-------------|-------------|-------------|-------------|
| GO:0010001~glial cell differentiation                           | 3 | 0.029505104 | SOX10, PLP1, NKX6-2                              | 11.02922078 | 1           | 0.613601108 | 37.75829874 |
| GO:0051253~negative regulation of RNA metabolic process         | 6 | 0.029678251 | EPC1, RHOX3A, NKX6-2, ZFP639, FOXP3, MYC         | 3.415500628 | 1           | 0.604483881 | 37.93387095 |
| GO:0031327~negative regulation of cellular biosynthetic process | 7 | 0.03304789  | EPC1, RHOX3A, NKX6-2, ZFP639, INPP5D, FOXP3, MYC | 2.872727273 | 1           | 0.63367545  | 41.25970041 |
| GO:0002764~immune response-regulating signal transduction       | 3 | 0.034192871 | PTPN6, CLEC7A, FOXP3                             | 10.18081918 | 1           | 0.635757935 | 42.35125793 |
| GO:0051250~negative regulation of lymphocyte activation         | 3 | 0.034192871 | PTPN6, INPP5D, FOXP3                             | 10.18081918 | 1           | 0.635757935 | 42.35125793 |
| GO:0042063~gliogenesis  | 3 | 0.034192871 | SOX10, PLP1, NKX6-2                              | 10.18081918 | 1           | 0.635757935 | 42.35125793 |
| GO:0009890~negative regulation of biosynthetic process          | 7 | 0.034347445 | EPC1, RHOX3A, NKX6-2, ZFP639, INPP5D, FOXP3, MYC | 2.846250524 | 1           | 0.627083249 | 42.49715594 |
| GO:0030247~polysaccharide binding                               | 4 | 0.034498539 | FGFR2, TNFAIP6, LIPG, CLEC7A                     | 5.536666667 | 0.997055665 | 0.565062603 | 34.72659028 |
| GO:0001871~pattern binding                                      | 4 | 0.034498539 | FGFR2, TNFAIP6, LIPG, CLEC7A                     | 5.536666667 | 0.997055665 | 0.565062603 | 34.72659028 |
| GO:0002695~negative regulation of leukocyte activation          | 3 | 0.035407391 | PTPN6, INPP5D, FOXP3                             | 9.988728253 | 1           | 0.628385387 | 43.48832353 |
| GO:0050866~negative regulation of cell activation               | 3 | 0.035407391 | PTPN6, INPP5D, FOXP3                             | 9.988728253 | 1           | 0.628385387 | 43.48832353 |
| GO:0050864~regulation of B cell                                 | 3 | 0.037885977 | PTPN6, INPP5D, FOXP3                             | 9.625501771 | 1           | 0.643933784 | 45.74395833 |

|   |   |             |                                  |             |   |             |             |
|---|---|-------------|----------------------------------|-------------|---|-------------|-------------|
| activation  |   |             |                                  |             |   |             |             |
| GO:0043473~pigmentation   | 3 | 0.039149609 | SOX10, MITF, MYC                 | 9.453617811 | 1 | 0.646686201 | 46.8611923  |
| GO:0000122~negative regulation of transcription from RNA polymerase II promoter | 5 | 0.040390134 | EPC1, RHOX3A, NKX6-2, FOXP3, MYC | 3.81964356  | 1 | 0.649082121 | 47.93700075 |
| GO:0045619~regulation of lymphocyte differentiation                             | 3 | 0.041724479 | PTPN6, INPP5D, FOXP3             | 9.12763099  | 1 | 0.652205314 | 49.07137621 |
| GO:0001817~regulation of cytokine production                                    | 4 | 0.042885669 | INPP5D, CLEC7A, TRAF6, FOXP3     | 5.078202373 | 1 | 0.653657553 | 50.03966134 |
| GO:0045165~cell fate commitment   | 4 | 0.049222374 | FGFR2, WNT3, NKX6-2, MITF        | 4.801837618 | 1 | 0.696574872 | 55.02687019 |
| GO:0042035~regulation of cytokine biosynthetic process                          | 3 | 0.049814847 | INPP5D, TRAF6, FOXP3             | 8.271915584 | 1 | 0.692693259 | 55.46850558 |

### E. Enriched GO terms of up-regulated DEGs in short-term PFC.

| Term  | Count | PValue   | Genes  | Fold Enrichment | Bonferroni  | Benjamini   | FDR         |
|---|-------|----------|--|-----------------|-------------|-------------|-------------|
| GO:0030017~sarcomere                          | 10    | 7.18E-08 | TNNT2, ACTC1, DES, TCAP, PDLIM5, LDB3, MYOZ2, TNNI3, TPM1, CSRP3     | 12.81147541     | 1.41E-05    | 1.41E-05    | 8.98E-05    |
| GO:0044449~contractile fiber part             | 10    | 1.36E-07 | TNNT2, ACTC1, DES, TCAP, PDLIM5, LDB3, MYOZ2, TNNI3, TPM1, CSRP3     | 11.91765154     | 2.67E-05    | 1.34E-05    | 1.70E-04    |
| GO:0030016~myofibril                          | 10    | 2.22E-07 | TNNT2, ACTC1, DES, TCAP, PDLIM5, LDB3, MYOZ2, TNNI3, TPM1, CSRP3     | 11.26283553     | 4.37E-05    | 1.46E-05    | 2.78E-04    |
| GO:0043292~contractile fiber                  | 10    | 3.22E-07 | TNNT2, ACTC1, DES, TCAP, PDLIM5, LDB3, MYOZ2, TNNI3, TPM1, CSRP3     | 10.78861087     | 6.35E-05    | 1.59E-05    | 4.03E-04    |
| GO:0048738~cardiac muscle tissue development  | 8     | 8.97E-07 | TNNT2, ACTC1, XIRP1, GATA6, PLN, NKX2-5, TPM1, CSRP3                 | 15.01643873     | 9.45E-04    | 9.45E-04    | 0.001426997 |
| GO:0007517~muscle organ development           | 11    | 5.43E-06 | TNNT2, APP, ACTC1, DES, XIRP1, GATA6, PLN, ETV1, NKX2-5, TPM1, CSRP3 | 6.687007874     | 0.005705993 | 0.002857078 | 0.008635034 |
| GO:0031674~I band                             | 7     | 1.15E-05 | ACTC1, DES, TCAP, PDLIM5, LDB3, MYOZ2, CSRP3                         | 13.53665326     | 0.002259003 | 4.52E-04    | 0.014352334 |
| GO:0014706~striated muscle tissue development | 9     | 2.33E-05 | TNNT2, APP, ACTC1, XIRP1, GATA6, PLN, NKX2-5, TPM1, CSRP3            | 7.582119164     | 0.024267717 | 0.008155572 | 0.037066514 |

|   |    |            |   |             |             |             |             |
|---|----|------------|---|-------------|-------------|-------------|-------------|
| GO:0060537~muscle tissue development            | 9  | 3.82E-05   | TNNT2, APP, ACTC1, XIRP1, GATA6, PLN, NKX2-5, TPM1, CSRP3               | 7.080361278 | 0.039442316 | 0.010009875 | 0.060708444 |
| GO:0007507~heart development                    | 11 | 4.25E-05   | TNNT2, ACTC1, TCAP, XIRP1, GATA6, PLN, NPPB, TNNT3, NKX2-5, TPM1, CSRP3 | 5.277638501 | 0.043758864 | 0.008909109 | 0.067500821 |
| GO:0030018~Z disc                               | 6  | 7.80E-05   | DES, TCAP, PDLIM5, LDB3, MYOZ2, CSRP3                                   | 13.36849608 | 0.015240275 | 0.002556327 | 0.097422152 |
| GO:0008016~regulation of heart contraction      | 6  | 9.60E-05   | TNNT2, GNAI3, PLN, NKX2-5, TPM1, CSRP3                                  | 12.83905512 | 0.096280141 | 0.016731097 | 0.152655424 |
| GO:0051146~striated muscle cell differentiation | 7  | 1.75E-04   | TNNT2, APP, ACTC1, TCAP, XIRP1, GATA6, NKX2-5                           | 8.415111032 | 0.168327959 | 0.025987376 | 0.277761053 |
| GO:0055001~muscle cell development              | 6  | 2.49E-04   | TNNT2, APP, ACTC1, TCAP, XIRP1, NKX2-5                                  | 10.52381567 | 0.230549063 | 0.032228972 | 0.394713303 |
| GO:0044057~regulation of system process         | 9  | 5.64E-04   | TNNT2, GNAI3, TNNT1, PLN, TNNT3, NKX2-5, TPM1, CSRP3, CASQ2             | 4.790692208 | 0.44846247  | 0.063977865 | 0.893945871 |
| GO:0030239~myofibril assembly                   | 4  | 6.77E-04   | TNNT2, ACTC1, TCAP, XIRP1   | 22.5246581  | 0.510109817 | 0.068870956 | 1.071056532 |
| GO:0042692~muscle cell differentiation          | 7  | 7.62E-04   | TNNT2, APP, ACTC1, TCAP, XIRP1, GATA6, NKX2-5                           | 6.401238307 | 0.552399668 | 0.070471385 | 1.20574526  |
| GO:0031032~actomyosin structure organization    | 4  | 0.00154253 | TNNT2, ACTC1, TCAP, XIRP1   | 17.11874016 | 0.803497905 | 0.126799588 | 2.425482695 |
| GO:0055002~striated muscle cell                 | 5  | 0.00155807 | TNNT2, APP, ACTC1, TCAP, XIRP1  | 9.906678332 | 0.806695011 | 0.118757122 | 2.449633929 |

|  |    |             |   |             |             |             |             |
|--|----|-------------|---|-------------|-------------|-------------|-------------|
| development  |    |             |   |             |             |             |             |
| GO:0055007~cardiac muscle cell differentiation                   | 4  | 0.002153057 | ACTC1, XIRP1, GATA6, NKX2-5   | 15.28458943 | 0.896870333 | 0.149787666 | 3.370159736 |
| GO:0044093~positive regulation of molecular function             | 10 | 0.002181731 | MEN1, OPRM1, ADCY3, CASP8AP2, IKBKG, PICK1, NRK, LPAR1, APAF1, NKX2-5 | 3.496474705 | 0.899947145 | 0.142273886 | 3.414316717 |
| GO:0005200~structural constituent of cytoskeleton                | 4  | 0.002715894 | TNNT2, DES, ODF2, TPM1  | 14.09867374 | 0.489180189 | 0.489180189 | 3.464845727 |
| GO:0043085~positive regulation of catalytic activity             | 9  | 0.002975534 | MEN1, OPRM1, ADCY3, CASP8AP2, IKBKG, PICK1, NRK, LPAR1, APAF1         | 3.689383655 | 0.956755634 | 0.178238868 | 4.629246745 |
| GO:0035051~cardiac cell differentiation                          | 4  | 0.003466997 | ACTC1, XIRP1, GATA6, NKX2-5   | 12.96874254 | 0.974282009 | 0.193722516 | 5.374245865 |
| GO:0016563~transcription activator activity                      | 9  | 0.003752416 | CUTA, NACA, GATA6, MITF, ETV1, NPAS4, FOXP3, NKX2-5, HMGA1            | 3.551885952 | 0.604889577 | 0.371421904 | 4.757736133 |
| GO:0045214~sarcomere organization                                | 3  | 0.004441982 | TNNT2, TCAP, XIRP1  | 29.17967072 | 0.990834217 | 0.229474175 | 6.836091743 |
| GO:0010927~cellular component assembly involved in morphogenesis | 4  | 0.004446445 | TNNT2, ACTC1, TCAP, XIRP1   | 11.888014   | 0.990877423 | 0.21902386  | 6.842734407 |
| GO:0003007~heart   | 5  | 0.004918332 | TNNT2, ACTC1, XIRP1, NKX2-5, TPM1                                     | 7.229197702 | 0.994465265 | 0.22882163  | 7.542587331 |

|  |    |             |   |             |             |             |             |
|--|----|-------------|---|-------------|-------------|-------------|-------------|
| morphogenesis  |    |             |   |             |             |             |             |
| GO:0006937~regulation of muscle contraction                  | 4  | 0.006419329 | TNNC1, TNNI3, NKX2-5, CASQ2   | 10.43825619 | 0.998872534 | 0.276190997 | 9.73608623  |
| GO:0055006~cardiac cell development                          | 3  | 0.007217066 | ACTC1, XIRP1, NKX2-5  | 22.92688414 | 0.999516457 | 0.293206536 | 10.88192649 |
| GO:0055013~cardiac muscle cell development                   | 3  | 0.007217066 | ACTC1, XIRP1, NKX2-5  | 22.92688414 | 0.999516457 | 0.293206536 | 10.88192649 |
| GO:0045859~regulation of protein kinase activity             | 7  | 0.007715875 | CAV3, APP, IKBKG, PICK1, FABP4, NRK, LPAR1                            | 4.026585387 | 0.999715299 | 0.298798191 | 11.59145678 |
| GO:0043549~regulation of kinase activity                     | 7  | 0.008950853 | CAV3, APP, IKBKG, PICK1, FABP4, NRK, LPAR1                            | 3.900754593 | 0.999923382 | 0.32622662  | 13.32543569 |
| GO:0051338~regulation of transferase activity                | 7  | 0.010563808 | CAV3, APP, IKBKG, PICK1, FABP4, NRK, LPAR1                            | 3.76354212  | 0.999986236 | 0.360928706 | 15.54214596 |
| GO:0055008~cardiac muscle tissue morphogenesis               | 3  | 0.011844349 | TNNT2, ACTC1, TPM1  | 17.832021   | 0.999996485 | 0.383081197 | 17.26406057 |
| GO:0060415~muscle tissue morphogenesis                       | 3  | 0.011844349 | TNNT2, ACTC1, TPM1  | 17.832021   | 0.999996485 | 0.383081197 | 17.26406057 |
| GO:0010558~negative regulation of macromolecule biosynthetic | 10 | 0.015777482 | MEN1, SATB1, RHOX3A, EIF4EBP2, TIMELESS, NR6A1, FABP4, ZFP639, FOXP3, | 2.559620239 | 0.999999947 | 0.462494663 | 22.34941843 |

|   |    |             |  |             |             |             |             |
|---|----|-------------|--|-------------|-------------|-------------|-------------|
| process   |    |             | NKX2-5   |             |             |             |             |
| GO:0043009~chordate embryonic development                                       | 10 | 0.016454675 | MEN1, WNT7B, TCAP, GATA6, NASP, DAD1, APAF1, TRAF6, NKX2-5, TPM1             | 2.541380665 | 0.999999975 | 0.464499572 | 23.1948691  |
| GO:0009792~embryonic development ending in birth or egg hatching                | 10 | 0.017390587 | MEN1, WNT7B, TCAP, GATA6, NASP, DAD1, APAF1, TRAF6, NKX2-5, TPM1             | 2.517461788 | 0.999999991 | 0.471450274 | 24.34913025 |
| GO:0031327~negative regulation of cellular biosynthetic process                 | 10 | 0.018614697 | MEN1, SATB1, RHOX3A, EIF4EBP2, TIMELESS, NR6A1, FABP4, ZFP639, FOXP3, NKX2-5 | 2.488188976 | 0.999999997 | 0.483231325 | 25.83429944 |
| GO:0009890~negative regulation of biosynthetic process                          | 10 | 0.01963839  | MEN1, SATB1, RHOX3A, EIF4EBP2, TIMELESS, NR6A1, FABP4, ZFP639, FOXP3, NKX2-5 | 2.465256359 | 0.999999999 | 0.490511858 | 27.05528421 |
| GO:0000122~negative regulation of transcription from RNA polymerase II promoter | 7  | 0.020612585 | MEN1, SATB1, RHOX3A, TIMELESS, NR6A1, FOXP3, NKX2-5                          | 3.242185636 | 1           | 0.496424636 | 28.19971678 |
| GO:0002637~regulation of immunoglobulin production                              | 3  | 0.022265957 | TNFSF13, TRAF6, FOXP3  | 12.83905512 | 1           | 0.51285723  | 30.10358437 |
| GO:0005856~cytoskeleton   | 19 | 0.022367384 | ACTC1, MYL3, PICK1, CETN4, MICAL3, LDB3, MYOZ2, HOMER2, TPM1, CSRP3,         | 1.735600947 | 0.988395956 | 0.470926973 | 24.63544593 |



|  |    |             |   |             |   |             |             |
|--|----|-------------|---|-------------|---|-------------|-------------|
|  |    |             | TNNT2, APP, FRMD6, DES, MFAP2, ODF2,<br>SKA1, CDC42EP4, SGCA                        |             |   |             |             |
| GO:0016481~negative regulation of transcription                              | 9  | 0.022485231 | MEN1, SATB1, RHOX3A, TIMELESS, NR6A1, FABP4, ZFP639, FOXP3, NKX2-5                  | 2.588519177 | 1 | 0.505890544 | 30.35249593 |
| GO:0048729~tissue morphogenesis  | 7  | 0.023460626 | TNNT2, ACTC1, TIMELESS, GRSF1, APAF1, TRAF6, TPM1                                   | 3.146827235 | 1 | 0.510768453 | 31.44969676 |
| GO:0045597~positive regulation of cell differentiation                       | 6  | 0.023467025 | MEN1, WNT7B, CD36, GATA6, FOXP3, NKX2-5   | 3.668301462 | 1 | 0.501051489 | 31.45684124 |
| GO:0045892~negative regulation of transcription, DNA-dependent               | 8  | 0.024608079 | MEN1, SATB1, RHOX3A, TIMELESS, NR6A1, ZFP639, FOXP3, NKX2-5                         | 2.779016259 | 1 | 0.508241231 | 32.71970321 |
| GO:0051253~negative regulation of RNA metabolic process                      | 8  | 0.025377589 | MEN1, SATB1, RHOX3A, TIMELESS, NR6A1, ZFP639, FOXP3, NKX2-5                         | 2.761087122 | 1 | 0.509818626 | 33.55901155 |
| GO:0006357~regulation of transcription from RNA polymerase II promoter       | 12 | 0.027929135 | MEN1, SATB1, APP, RHOX3A, TIMELESS, MED15, GATA6, MITF, NR6A1, NPAS4, FOXP3, NKX2-5 | 2.084262194 | 1 | 0.53491902  | 36.27232387 |
| GO:0002700~regulation of production of molecular mediator of immune response | 3  | 0.031332621 | TNFSF13, TRAF6, FOXP3   | 10.6992126  | 1 | 0.567782171 | 39.73018756 |
| GO:0045934~negative regulation   | 9  | 0.03146725  | MEN1, SATB1, RHOX3A, TIMELESS, NR6A1,   | 2.425514191 | 1 | 0.560421767 | 39.86328346 |

|  |    |             |   |             |             |             |             |
|--|----|-------------|---|-------------|-------------|-------------|-------------|
| of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process     |    |             | FABP4, ZFP639, FOXP3, NKX2-5  |             |             |             |             |
| GO:0005788~endoplasmic reticulum lumen                                       | 4  | 0.032527044 | P4HA1, SDF2L1, HSPA5, CASQ2   | 5.693989071 | 0.998517993 | 0.557048387 | 33.86319777 |
| GO:0051172~negative regulation of nitrogen compound metabolic process        | 9  | 0.03310425  | MEN1, SATB1, RHOX3A, TIMELESS, NR6A1, FABP4, ZFP639, FOXP3, NKX2-5  | 2.401319536 | 1           | 0.570365778 | 41.45975825 |
| GO:0003705~RNA polymerase II transcription factor activity, enhancer binding | 3  | 0.034076709 | GATA6, MITF, FOXP3  | 10.22153846 | 0.999809089 | 0.942419262 | 36.20861829 |
| GO:0010629~negative regulation of gene expression                            | 9  | 0.036998681 | MEN1, SATB1, RHOX3A, TIMELESS, NR6A1, FABP4, ZFP639, FOXP3, NKX2-5  | 2.348607644 | 1           | 0.603111766 | 45.09958125 |
| GO:0051924~regulation of calcium ion transport                               | 3  | 0.039454414 | CAV3, PLN, NKX2-5   | 9.440481704 | 1           | 0.618735676 | 47.28455128 |
| GO:0030528~transcription regulator activity                                  | 19 | 0.043370971 | CUTA, SATB1, NACA, NR6A1, MITF, ZFP639, NPAS4, FOXP3, HMGA1, MEN1, MAX, RHOX3A, MED15, CASP8AP2, GATA6, XBP1, ETV1, FABP4, NKX2-5 | 1.610358464 | 0.999982475 | 0.935298469 | 43.72499803 |

|   |    |             |  |             |   |             |             |
|---|----|-------------|--|-------------|---|-------------|-------------|
| GO:0043280~positive regulation of caspase activity  | 3  | 0.04378222  | MEN1, CASP8AP2, APAF1  | 8.916010499 | 1 | 0.649573138 | 50.93809842 |
| GO:0010952~positive regulation of peptidase activity  | 3  | 0.04378222  | MEN1, CASP8AP2, APAF1  | 8.916010499 | 1 | 0.649573138 | 50.93809842 |
| GO:0042592~homeostatic process  | 11 | 0.044888145 | MEN1, CAV3, APP, XIRP1, PLN, IKBKG, FABP4, TNNI3, FOXP3, CSRP3, GLRX2        | 2.015262647 | 1 | 0.650874287 | 51.83289363 |
| GO:0051890~regulation of cardioblast differentiation  | 2  | 0.045519087 | GATA6, NKX2-5  | 42.79685039 | 1 | 0.648221111 | 52.33650958 |
| GO:0051891~positive regulation of cardioblast differentiation   | 2  | 0.045519087 | GATA6, NKX2-5  | 42.79685039 | 1 | 0.648221111 | 52.33650958 |
| GO:0010605~negative regulation of macromolecule metabolic process                                       | 10 | 0.045706679 | MEN1, SATB1, RHOX3A, EIF4EBP2, TIMELESS, NR6A1, FABP4, ZFP639, FOXP3, NKX2-5 | 2.114468893 | 1 | 0.642028838 | 52.4852902  |
| GO:0045935~positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 10 | 0.047622527 | MEN1, APP, GATA6, MITF, ETV1, TNFSF13, NPAS4, FOXP3, NKX2-5, HMGA1           | 2.097884823 | 1 | 0.649909987 | 53.98004961 |
| GO:0007166~cell surface receptor linked signal transduction   | 32 | 0.048054537 | OLFR1257, OPRM1, GNAI3, VMN1R185, OLFR156, TRHR, MITF, OLFR1502, OLFR638,    | 1.3722437   | 1 | 0.645886566 | 54.31096198 |

|  |   |             |  |             |             |             |             |
|--|---|-------------|--|-------------|-------------|-------------|-------------|
|  |   |             | LPAR1, OLF434, GPR142, APP, EIF4EBP2,<br>OLFR554, OLF462, TAS2R140, OLF4183,<br>OLFR699, RXFP4, VMN1R116, LTK,<br>OLFR1280, PICK1, FOXP3, HOMER2,<br>OLFR1431, WNT7B, OLF464, WNT9B,<br>OLFR1417, OLF494 |             |             |             |             |
| GO:0051094~positive regulation<br>of developmental process | 6 | 0.049009621 | MEN1, WNT7B, CD36, GATA6, FOXP3,<br>NKX2-5   | 2.999779233 | 1           | 0.646024492 | 55.03464335 |
| GO:0045121~membrane raft                                   | 4 | 0.049267886 | CAV3, ADCY3, CD36, SGCA  | 4.823143684 | 0.999952416 | 0.669084139 | 46.83050674 |

### F. Enriched GO terms of down-regulated DEGs in short-term PFC.

| Term  | Count | PValue      | Genes  | Fold Enrichment | Bonferroni  | Benjamini   | FDR         |
|---|-------|-------------|--|-----------------|-------------|-------------|-------------|
| GO:0003700~transcription factor activity    | 21    | 0.001039075 | ZBTB7B, ISX, E2F2, GSX2, NKX2-6, MTA3, GABPA, CBFA2T3, HOXD11, MSX2, IRF9, HAND1, ZSCAN21, ZGLP1, HOPX, CREB3L2, LHX6, MESP2, LBX2, LHX9, NFATC1                               | 2.233527566     | 0.279261426 | 0.279261426 | 1.389823895 |
| GO:0030528~transcription regulator activity | 25    | 0.009717098 | ISX, E2F2, CBFA2T3, HOXD11, MSX2, HAND1, ZSCAN21, CREB3L2, LHX6, LHX9, NFATC1, ZBTB7B, UTF1, GSX2, NKX2-6, MTA3, GABPA, PRPF6, IRF9, BHLHA9, ZGLP1, HOPX, MAP3K10, LBX2, MESP2 | 1.710907162     | 0.953849813 | 0.785174053 | 12.31814871 |
| GO:0043565~sequence-specific DNA binding    | 14    | 0.016880474 | ISX, GSX2, NKX2-6, MTA3, GABPA, HOXD11, MSX2, ZGLP1, HOPX, CREB3L2, LHX6, LHX9, LBX2, NFATC1   | 2.078198311     | 0.995311959 | 0.832635328 | 20.48239488 |
| GO:0048663~neuron fate commitment           | 4     | 0.018687853 | WNT1, GSX2, LHX6, DLL1   | 7.051375195     | 1           | 1           | 26.24383581 |
| GO:0045449~regulation of transcription      | 38    | 0.021818966 | ISX, E2F2, ZBTB33, CBFA2T3, LIN28A, HOXD11, MSX2, HAND1, ZSCAN21,  | 1.413757981     | 1           | 0.999997823 | 29.95095957 |

|   |    |             |  |             |   |             |             |
|---|----|-------------|--|-------------|---|-------------|-------------|
|   |    |             | CREB3L2, CASZ1, LHX6, LHX9, NFATC1, ZBTB7B, KAT2A, IRAK1, MAGEL2, UTF1, IL5, GSX2, NKX2-6, MTA3, GABPA, KLF14, MBD1, PRPF6, IRF9, BHLHA9, ZGLP1, SP4, MAP3K10, HOPX, BRDT, MESP2, LBX2, KDM4D, SUDS3 |             |   |             |             |
| GO:0043009~chordate embryonic development               | 11 | 0.030510553 | KAT2A, HBA-A2, WNT1, HAND1, NKX2-6, VANGL2, GABPA, HOPX, DLL1, AMBRA1, MESP2   | 2.164822432 | 1 | 0.999995011 | 39.34654581 |
| GO:0051252~regulation of RNA metabolic process          | 27 | 0.031530759 | ISX, E2F2, RBM5, LIN28A, CBFA2T3, HOXD11, MSX2, HAND1, ZSCAN21, CREB3L2, LHX6, LHX9, NFATC1, ZBTB7B, KAT2A, UTF1, IL5, GSX2, NKX2-6, MTA3, GABPA, PRPF6, IRF9, ZGLP1, HOPX, LBX2, MESP2              | 1.503392998 | 1 | 0.999922667 | 40.36830412 |
| GO:0045165~cell fate commitment                         | 6  | 0.032053724 | WNT1, HAND1, GSX2, LHX6, DLL1, HOXD11  | 3.381781981 | 1 | 0.999547898 | 40.88578367 |
| GO:0009792~embryonic development ending in birth or egg | 11 | 0.032249054 | KAT2A, HBA-A2, WNT1, HAND1, NKX2-6, VANGL2, GABPA, HOPX, DLL1, AMBRA1,   | 2.144447633 | 1 | 0.998431696 | 41.07798188 |

|   |    |             |   |             |             |             |             |
|---|----|-------------|---|-------------|-------------|-------------|-------------|
| hatching  |    |             | MESP2   |             |             |             |             |
| GO:0008380~RNA splicing                               | 7  | 0.034235454 | PPIH, RBM5, CELF2, WBP11, LSM10, CWC22, PRPF6   | 2.885450795 | 1           | 0.997211287 | 42.99952685 |
| GO:0045095~keratin filament                           | 4  | 0.038747262 | KRT81, GM11938, KRT86, KRTAP10-10   | 5.316326531 | 0.999247613 | 0.999247613 | 38.59379534 |
| GO:0006355~regulation of transcription, DNA-dependent | 26 | 0.044217415 | ISX, E2F2, LIN28A, CBFA2T3, HOXD11, MSX2, HAND1, ZSCAN21, CREB3L2, LHX6, LHX9, NFATC1, ZBTB7B, KAT2A, UTF1, IL5, GSX2, NKX2-6, MTA3, GABPA, PRPF6, IRF9, ZGLP1, HOPX, LBX2, MESP2 | 1.470440356 | 1           | 0.998746689 | 51.79753428 |
| GO:0003002~regionalization                            | 7  | 0.044246595 | KAT2A, WNT1, GSX2, DLL1, SP8, MESP2, HOXD11   | 2.710166401 | 1           | 0.997377259 | 51.82127534 |
| GO:0006879~cellular iron ion homeostasis              | 3  | 0.047000551 | 1600014K23RIK, ALAS2, HAMP  | 8.571068124 | 1           | 0.996621288 | 54.01319355 |
| GO:0005179~hormone activity                           | 5  | 0.047565088 | SCT, NTS, HAMP, IGF2, INSL6   | 3.651954048 | 0.999999785 | 0.978458279 | 48.11136188 |

### G. Enriched GO terms of up-regulated DEGs in short-term hippocampus.

| Term  | Count | PValue      | Genes   | Fold Enrichment | Bonferroni  | Benjamini   | FDR         |
|---|-------|-------------|---|-----------------|-------------|-------------|-------------|
| GO:0044265~cellular macromolecule catabolic process | 9     | 0.010762443 | SENP3, RNF6, USPL1, ZCCHC11, USP5, ADAM17, CDC23, DNASE1L2, USP32   | 2.910259156     | 0.999038426 | 0.999038426 | 14.89582135 |
| GO:0009057~macromolecule catabolic process          | 9     | 0.015996502 | SENP3, RNF6, USPL1, ZCCHC11, USP5, ADAM17, CDC23, DNASE1L2, USP32   | 2.710011966     | 0.999968096 | 0.994351643 | 21.36638577 |
| GO:0030054~cell junction                            | 7     | 0.019632138 | SYNPR, OCLN, GABRA3, GABRB2, MPP7, HOMER2, GAK  | 3.210858401     | 0.945775854 | 0.945775854 | 21.0175443  |
| GO:0008270~zinc ion binding                         | 18    | 0.025609357 | ZFP62, BRD1, ZCCHC11, CAR13, USP5, ZHX1, ZFP719, TRIM23, ZIC1, DMRTB1, ZIC3, ZIC2, RNF6, ZSCAN21, ZFP191, NBR1, ADAM17, ADAM9 | 1.695919453     | 0.990865348 | 0.990865348 | 27.37405138 |
| GO:0005615~extracellular space                      | 7     | 0.028203017 | BMP4, CCL3, CXCL5, PSAP, GPX3, ADAM9, SPP1  | 2.953235711     | 0.985085616 | 0.877875539 | 28.85406716 |
| GO:0043167~ion binding                              | 28    | 0.0325581   | ZFP62, MMGT1, GABRB2, USP5, ZFP719, ZIC1, CANX, ZIC3, CALU, ZIC2, P4HA1, ZSCAN21, ZFP191, ACSL3, PLS3, ADAM9, BRD1,           | 1.411589738     | 0.997499047 | 0.949990467 | 33.50774722 |



|   |    |             |  |             |             |             |             |
|---|----|-------------|--|-------------|-------------|-------------|-------------|
|   |    |             | ZCCHC11, CAR13, GABRA3, ZHX1,<br>CACNG5, TRIM23, DMRTB1, RNF6,<br>NBR1, ADAM17, NEK6                             |             |             |             |             |
| GO:0007049~cell cycle                                       | 8  | 0.032564621 | CDKN1C, TXNIP, CAMK2D, AHCTF1,<br>CDC23, CABLES1, NEK6, GAK  | 2.57842928  | 0.999999999 | 0.999162277 | 38.9505706  |
| GO:0006511~ubiquitin-dependent<br>protein catabolic process | 4  | 0.033602014 | RNF6, USPL1, USP5, USP32   | 5.586596773 | 1           | 0.995854847 | 39.91913309 |
| GO:0000278~mitotic cell cycle                               | 5  | 0.033793392 | CAMK2D, AHCTF1, CDC23, CABLES1,<br>NEK6  | 4.035400333 | 1           | 0.987894342 | 40.09623969 |
| GO:0019887~protein kinase regulator<br>activity             | 3  | 0.034672358 | CDKN1C, CABLES1, TRIB2   | 10.08449279 | 0.998316829 | 0.881046803 | 35.27728056 |
| GO:0005783~endoplasmic reticulum                            | 9  | 0.03519508  | MMGT1, SLN, P4HA1, A130022J15RIK,<br>HSPA5, ACSL3, CANX, DERL3, CALU   | 2.315364991 | 0.994840496 | 0.827203089 | 34.71227836 |
| GO:0005576~extracellular region                             | 14 | 0.036354249 | BMP4, CCL3, IGFBPL1, CXCL5, PSAP,<br>DNASE1L2, CALU, SOST,<br>A130022J15RIK, GPX3, ADAM17,<br>HSPA5, SPP1, ADAM9 | 1.796551724 | 0.995676262 | 0.743572355 | 35.63962282 |
| GO:0005788~endoplasmic reticulum<br>lumen                   | 3  | 0.042583362 | P4HA1, HSPA5, CALU   | 8.982758621 | 0.998333357 | 0.721792694 | 40.41963146 |

|   |   |             |   |             |             |             |             |
|---|---|-------------|---|-------------|-------------|-------------|-------------|
| GO:0022402~cell cycle process               | 6 | 0.046664982 | CDKN1C, CAMK2D, AHCTF1, CDC23,<br>CABLES1, NEK6 | 3.006527271 | 1           | 0.993984477 | 50.95045713 |
| GO:0004221~ubiquitin thiolesterase activity | 3 | 0.048492156 | USPL1, USP5, USP32                              | 8.380071474 | 0.999876223 | 0.894522488 | 45.81878183 |

## H. Enriched GO terms of down-regulated DEGs in short-term hippocampus.

| Term  | Count | PValue      | Genes                             | Fold Enrichment | Bonferroni  | Benjamini   | FDR         |
|---|-------|-------------|-----------------------------------|-----------------|-------------|-------------|-------------|
| GO:0000785~chromatin  | 4     | 0.003291125 | SIRT6, 1700014N06RIK, HMGA1, CHD3 | 12.63030303     | 0.160305618 | 0.160305618 | 3.165108891 |
| GO:0006333~chromatin assembly or disassembly                          | 3     | 0.008016087 | SET, 1700014N06RIK, CHD3          | 20.77675841     | 0.761315608 | 0.761315608 | 9.421280635 |
| GO:0044427~chromosomal part   | 4     | 0.019798113 | SIRT6, 1700014N06RIK, HMGA1, CHD3 | 6.553459119     | 0.653483991 | 0.411343896 | 17.72459723 |
| GO:0019941~modification-dependent protein catabolic process           | 4     | 0.023899893 | DZIP3, GM2933, PCNP, FBXL13       | 5.944006999     | 0.986510491 | 0.883855654 | 25.72572072 |
| GO:0043632~modification-dependent macromolecule catabolic process     | 4     | 0.023899893 | DZIP3, GM2933, PCNP, FBXL13       | 5.944006999     | 0.986510491 | 0.883855654 | 25.72572072 |
| GO:0051603~proteolysis involved in cellular protein catabolic process | 4     | 0.027215179 | DZIP3, GM2933, PCNP, FBXL13       | 5.654598419     | 0.992638136 | 0.805465817 | 28.76844854 |
| GO:0044257~cellular protein catabolic process                         | 4     | 0.027613104 | DZIP3, GM2933, PCNP, FBXL13       | 5.623008483     | 0.993155222 | 0.712366249 | 29.12585646 |
| GO:0030163~protein catabolic process                                  | 4     | 0.03020727  | DZIP3, GM2933, PCNP, FBXL13       | 5.430855316     | 0.9957455   | 0.664440373 | 31.41580029 |
| GO:0005694~chromosome   | 4     | 0.03100523  | SIRT6, 1700014N06RIK, HMGA1, CHD3 | 5.513227513     | 0.811619498 | 0.426748346 | 26.45636772 |

|   |   |             |                             |             |             |             |             |
|---|---|-------------|-----------------------------|-------------|-------------|-------------|-------------|
| GO:0044265~cellular macromolecule catabolic process | 4 | 0.038117579 | DZIP3, GM2933, PCNP, FBXL13 | 4.958219303 | 0.999009821 | 0.684291961 | 37.98548773 |
| GO:0009057~macromolecule catabolic process          | 4 | 0.045606711 | DZIP3, GM2933, PCNP, FBXL13 | 4.617057424 | 0.999753695 | 0.694862102 | 43.66759462 |